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Preface
Major depression is a prevalent and severe brain disorder with a high disabil-
ity burden, as measured by the Disability-Adjusted Life Years (DALY) metric. 
Antidepressants were discovered and developed starting in the 1950s and 1960s, 
however, all ‘early’ antidepressants were discovered by chance. Based on these early
medications, intense research into new and better antidepressants was undertaken, 
leading to the development of selective serotonin reuptake inhibitors (SSRIs). SSRIs
are a class of antidepressants popular in the late 1980s and 1990s that are still being 
used today. Although many new antidepressants with various mechanisms have
been found and introduced, we still have not seen ‘real’ antidepressants, defined 
as drugs that ‘repair’ or ‘improve’ the depression-causing mechanism in the brains
of depressed patients. Another worrying aspect is the limited efficacy of antide-
pressants; only around 50% of depressed patients respond to existing antidepres-
sants and a considerable number does not respond at all (i.e., treatment-resistant
depressed people). Another feature of present antidepressants is their slow onset of
action. It takes weeks to moths before a depressed patient experiences improvement
of symptoms (if a patient is a ‘responder’). All antidepressants have side effects that
may lead to cessation of treatment in an early phase before remission of depres-
sive symptoms can occur. Although initially developed as therapy for depression, 
antidepressants are often also therapeutically active in other psychiatric disorders, 
like anxiety and obsessive-compulsive disorders or alcohol use disorders.
All these aspects of antidepressants are reflected in the various sections and chap-
ters of this book. In Section 1, Berend Olivier (Chapter 1) gives an introductory
sketch of preclinical, clinical and translational aspects of various antidepressants, 
including the development of potential new antidepressants with less side effects or
faster onset of action and activity against treatment-resistant depression.
In Section 2 (Clinical Studies), Dr. Laura Orio et al. (Chapter 2) give an extensive
overview of the use of antidepressants in alcohol use disorders and these disorders’ 
comorbidity with depression. They particularly focus on the role of neurogenesis
in the therapeutic effects of antidepressants by increasing hippocampal plastic-
ity. They also discuss the possibility of implementing treatment during alcohol 
abstinence.
Dr. Ontiveros (Chapter 3) gives a thoughtful overview of treatment-resistant
depression (TRD), a condition with serious medical and psychosocial complica-
tions. An exact definition of TRD is still subject of debate and much research
still has to be done to find solutions. The chapter delves into this debate as well as
discusses the many strategies that have been applied to help patients recover from
severe depression.
In Section 3 (Preclinical and Translational Studies), Laura Staal and Jocelien Olivier
(Chapter 4) discuss the problems associated with antidepressant treatment during 
pregnancy. Unfortunately, approximately 20% of pregnant women suffer from
affective disorders. Treatment is beneficial for these women, but the long-term con-
sequences of in utero treatment for their offspring is unclear. Untreated depression
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probably has adverse effects on offspring too, and this complicates the decisions on 
how to treat. The complex interactions – ‘depression-mother-offspring-antidepres-
sant’ – are discussed in this intriguing contribution. The authors make clear that 
animal models are indispensable in making decisions on how to proceed.
The final two chapters deal with the search for new antidepressants. Dr. Marek et al. 
(Chapter 5) describe the theory of the potential of orexin2 receptor antagonists 
as antidepressants. In an animal model of depression, differential-reinforcement-
of-low-rate 72-second schedule (DRL 72s), the orexin2 receptor antagonist 
LSN2424100 had antidepressant-like effects, comparable to the reference tricyclic 
antidepressant imipramine.  Although clinical trials with orexin antagonists in 
depressed patients have not yet resulted in clear evidence for their antidepressant 
activity, this ‘orexin’ approach is a promising line of potential new antidepressants.
Dr. Tatiana Gudasheva et al. (Chapter 6) synthesize and further develop a low-
molecular dipeptide BDNF-loop-4-mimetic, GSB-106, as a potential antidepres-
sant, based on the role of BDNF in the pathophysiology of depression.  By using an 
animal model that induces a depression-like state in mice via social defeat stress, 
GSB-106, like the tricyclic antidepressant amitriptyline, induced an antidepressant-
like effect. Whether ligands that influence BDNF activity in the brain constitute 
putative new human antidepressants is a matter of future research.
This book nicely illustrates various aspects of the application of existing antidepres-
sants and the drug discovery process, which is trying to identify and develop new 
and hopefully better antidepressants.
Professor Dr. Berend Olivier


















Antidepressants - Preclinical, 
Clinical and Translational Aspects
Berend Olivier
1. Introduction
In 2011 two extensive studies were published about prevalence and associated 
disability, including the associated disease burden and financial costs, of brain 
diseases in Europe [1–3]. A shocking finding was that in a European population 
of more than 400 million people, approximately one-third suffered from a psy-
chiatric or neurological disorder. In the psychiatric disorders, anxiety disorders 
had the highest 12-month prevalence (14%) and depression (7%), approximately 
61.5 million people. The disability burden of psychiatric diseases including major 
depression is tremendous being defined in disability-adjusted life years (DALYs). 
In 2010, more than 26% of all cumulated disease burden in Europe was due to brain 
disorders; depression belongs to the top diseases with the highest DALYs. Major 
depression is a severe brain disorder associated with long-term disability and low 
quality of life. Suicide and suicidal attempts are highly associated with depression 
and have an enormous impact on relatives and society.
2. Antidepressants
Since the 1950s and 1960s of the last century, discovery and development of 
antidepressants have gradually emerged. Early antidepressants like imipramine and 
the irreversible monoamine oxidase inhibitors (MAOI) were discovered by seren-
dipity. These “accidental” discoveries have led to intensive research and have led 
to a series of new antidepressants, like the tricyclic class (TCA, e.g., imipramine, 
nortriptyline, amitriptyline, and clomipramine) and a series of (both reversible 
and irreversible) MAOIs. These antidepressants, although still clinically available, 
are not anymore first-line medicines, mainly because of their sometimes severe 
side effects. The research in the 1960s and 1970s led to the insight that TCAs block 
monoamine transporters (reuptake carriers) for serotonin and noradrenaline to 
varying extent. Some TCAs are preferential serotonin transporter (SERT) blockers 
(clomipramine, amitriptyline), while others are preferential noradrenaline trans-
porter (NET) blockers (desipramine, maprotiline) or mixed SERT/NET blockers 
(doxepin, imipramine). TCAs also block several neurotransmitter receptors, 
particularly muscarinic cholinergic, H1 histaminergic, and α1-adrenoceptors, which 
is mainly responsible for their (unwanted) side effects, including sedation, dry 
mouth, and constipation.
Based on the early, but overly simplistic hypothesis that low serotonin and/or 




Antidepressants - Preclinical, 
Clinical and Translational Aspects
Berend Olivier
1. Introduction
In 2011 two extensive studies were published about prevalence and associated 
disability, including the associated disease burden and financial costs, of brain 
diseases in Europe [1–3]. A shocking finding was that in a European population 
of more than 400 million people, approximately one-third suffered from a psy-
chiatric or neurological disorder. In the psychiatric disorders, anxiety disorders 
had the highest 12-month prevalence (14%) and depression (7%), approximately 
61.5 million people. The disability burden of psychiatric diseases including major 
depression is tremendous being defined in disability-adjusted life years (DALYs). 
In 2010, more than 26% of all cumulated disease burden in Europe was due to brain 
disorders; depression belongs to the top diseases with the highest DALYs. Major 
depression is a severe brain disorder associated with long-term disability and low 
quality of life. Suicide and suicidal attempts are highly associated with depression 
and have an enormous impact on relatives and society.
2. Antidepressants
Since the 1950s and 1960s of the last century, discovery and development of 
antidepressants have gradually emerged. Early antidepressants like imipramine and 
the irreversible monoamine oxidase inhibitors (MAOI) were discovered by seren-
dipity. These “accidental” discoveries have led to intensive research and have led 
to a series of new antidepressants, like the tricyclic class (TCA, e.g., imipramine, 
nortriptyline, amitriptyline, and clomipramine) and a series of (both reversible 
and irreversible) MAOIs. These antidepressants, although still clinically available, 
are not anymore first-line medicines, mainly because of their sometimes severe 
side effects. The research in the 1960s and 1970s led to the insight that TCAs block 
monoamine transporters (reuptake carriers) for serotonin and noradrenaline to 
varying extent. Some TCAs are preferential serotonin transporter (SERT) blockers 
(clomipramine, amitriptyline), while others are preferential noradrenaline trans-
porter (NET) blockers (desipramine, maprotiline) or mixed SERT/NET blockers 
(doxepin, imipramine). TCAs also block several neurotransmitter receptors, 
particularly muscarinic cholinergic, H1 histaminergic, and α1-adrenoceptors, which 
is mainly responsible for their (unwanted) side effects, including sedation, dry 
mouth, and constipation.
Based on the early, but overly simplistic hypothesis that low serotonin and/or 
noradrenalin levels/activity in the brain are associated (or even causative in) with 
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depression, the development of selective serotonin reuptake inhibitors (SSRIs; 
fluoxetine, fluvoxamine, sertraline, paroxetine, citalopram, escitalopram) and 
selective noradrenaline reuptake inhibitors (NRIs; reboxetine, atomoxetine) and 
mixed 5-HT/NA reuptake blockers (SNRIs: venlafaxine, duloxetine) was enabled. 
Several other antidepressants have been developed (e.g., bupropion, mirtazapine, 
agomelatine, trazodone, nefazodone), with variable mechanisms of action. In 
general, SSRIs are the drugs of choice and first-line in the treatment of major 
depression [4]. The first SSRIs (zimeldine, fluvoxamine) were introduced in the 
early 1980s [5], and in the ensuing decade, several followed (fluoxetine, paroxetine, 
sertraline). Up to this moment, SSRIs still are first-line medication in MDD, but 
some breakthrough antidepressants are emerging (esketamine), whereas extensive 
and intensive research and development are ongoing [6].
3. Antidepressants: how good are they?
SSRIs like all antidepressants come with associated problems, viz., (1) side 
effects, (2) limited efficacy, and (3) slow onset of action.
3.1 Side effects
Major depressive disorder (MDD) typically comes in recurrent depressive 
episodes rather than a single episode. Antidepressant treatment requires to focus on 
both acute and maintenance aspects of MDD. The primary goal of the acute treat-
ment phase (8–12 weeks) is to achieve symptomatic remission. In the acute phase, 
emerging side effects of the first-line treatment (often an SSRI) and the toler-
ance development of the patient strongly co-determine a positive antidepressant 
response to SSRIs or SNRIs. Main side effects (occurring in approximately 10–30% 
of patients) are nausea, dry mouth, sweating, sexual dysfunction, somnolence, 
nervousness, anxiety, dizziness, and insomnia [7]. If SSRI/SNRI treatment is not 
effective, MAO inhibitors or TCAs (as third-line treatments) may be used, although 
they come with additional and often more severe side effects. Second-line treatment 
includes novel antidepressants like vilazodone or vortioxetine or second-generation 
antidepressants like agomelatine, bupropion, or mirtazapine. All have their own 
side effect profile and are comparably effective antidepressant compared to SSRIs 
and others [8]. Lifetime major depression has high psychiatric comorbidity with 
anxiety disorders, substance use disorders, and impulse control disorders. Many 
depressed patients have medical (physical) comorbidities requiring pharmaco-
therapy, and this brings the risk of drug-drug interactions, often associated with 
cytochrome (CYP) P450 or P-glycoprotein-mediated effects. This may exacerbate 
side effects of drugs or interfere with the pharmacological action.
The most disturbing side effects of SSRIs and some TCAs (e.g., clomipramine) 
are those on sexual functioning like libido, orgasm, and arousal problems. In con-
trast to some other side effects that are prominent in the first phase of treatment, 
but often diminish upon drug continuation (like nausea and dizziness), sexual 
side effects do not disappear and are often causing drug discontinuation. MDD 
itself is already associated with 50–70% enhanced risk of sexual dysfunction (SD), 
and prescribing antidepressants with inherent effects on sexual behavior strongly 
enhances the risk for noncompliance or discontinued drug-taking [9]. Such a 
scenario can be avoided by prescribing (e.g., as second-line choice) antidepressants 
without (or less) sexual side effects (e.g., agomelatine, bupropion, vilazodone, or 
vortioxetine). Because depression occurs during all life phases, it is also common 
during pregnancy with an estimation of 20% of women that experience depressive 
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symptoms during that time [10], whereas around 4–8% of pregnant women suffer 
from MDD. Depression of the mother impacts the fetus, e.g., by the enhanced cor-
tisol levels in the mother which also pass the placenta. There is strong evidence that 
increased stress levels of the mother may lead to neurological and behavioral changes 
in the child which persists at least into adolescence (e.g., [11]). In the contribution 
of Staal and Olivier (Chapter 2), a review is given of the consequences of depression 
during pregnancy. Although the consequences for a child, adolescent, or adult that 
was in utero subject to a mother experiencing MDD are not yet completely clear, the 
first results point to a negative influence [12]. However, nowadays a considerable 
number (2–3%) of pregnant women with MDD are treated with antidepressants, 
mostly with SSRIs. SSRIs cross the placenta and reach the fetus, including the central 
nervous system. Because serotonin plays a key role in embryonic development as a 
neurotrophic factor, disturbances in its level might lead to (permanent) changes in 
the offspring [13–15]. Chapter 2 summarizes the state of the art of the interaction 
between untreated or SSRI-treated mothers with severe depression. It is not yet clear 
whether SSRI treatment or not is preferable for depression in pregnant women.
3.2 Limited efficacy
Antidepressants have limited efficacy in relieving depressive symptoms in 
MDD patients. It is estimated that approximately 50% of depressed patients are 
adequately treated by the available interventions, including pharmacotherapy [16]. 
Most patients receiving pharmacotherapy fail to achieve and sustain remission, 
eventually not leading to functional recovery. The majority of patients starting an 
antidepressant require several subsequent and different antidepressants or adjunc-
tive therapy (either pharmacological or cognitive behavioral therapy). There is 
evidence that if a chosen treatment strategy (a certain antidepressant, often an 
SSRI) results in symptomatic improvement within the first weeks, full remission is 
likely, but the reverse is also true: lack of early improvement predicts a high chance 
on non-remittance [17]. After failure of a number of (adequately dosed) antide-
pressants of different classes (SSRI, TCA, MAOI), and augmentation with various 
drugs (e.g., antipsychotics) and other strategies (e.g., cognitive behavioral ther-
apy), patients are considered treatment-resistant. Treatment-resistant depression 
(TRD) is defined as the failure to respond to one or more standard antidepressant 
treatment trials of adequate dosing and duration [18, 19]. TRD is a big challenge to 
treat. Although depression is diagnosed as a single entity, MDD [20] is an extremely 
heterogeneous disease [21] with regard to symptoms, etiologies, and pathophysiolo-
gies, with some moderately heritable background [22] and a high susceptibility to 
adverse life events [23]. TRD reflects a complex, heterogeneous state, probably with 
multiple causal underlying mechanisms. It is not clear how and where TRD patients 
differ from non-TRD patients, although early life stress seems to facilitate treat-
ment resistance [24]. Research is clearly needed to establish the pathophysiology of 
TRD, the complex mechanisms involved, and the heterogeneity of the TRD patient. 
Unfortunately, depression is presently not a high priority for pharmaceutical 
companies, due to recent failures in antidepressant discovery and lack of under-
standing of the mechanisms involved and the consequent lack of available targets. 
Akil et al. [21] argue a need of a fundamental approach in the search for new and 
effective treatments for TRD. They propose to identify dysfunctional brain circuitry 
in animal models of depression, looking at changes in associated gene expression. 
Combination of animal research with human genetic and imaging studies must 
generate circuits and molecules that are both altered in the animal models of TRD 
and also in selected patient populations. Such translational and highly integrated 
research may lead to new targets for specific anti-TRD medication.
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In Chapter 3 Marek and colleagues describe the research on orexin 2 receptor 
antagonists as putative new antidepressants. Orexin, a hypothalamic neuropeptide, 
is known for its involvement in sleep-wake cycling of all mammals, including 
man. Orexin 2 receptor antagonists produce antidepressant activity in animal tests 
sensitive for antidepressant activity, including the DRL-72 sec schedule of rein-
forcement, an advanced screen for antidepressants [25]. Both positive and negative 
preliminary human data are present on orexin 2 receptor antagonists in depression, 
but further studies are needed to answer whether this approach might lead to new 
antidepressants or may be also effective in treatment-resistant depression.
3.3 Slow onset of action
The current most widely prescribed antidepressants, SSRIs and SNRIs, but also 
TCAs and MAOIs and other antidepressants, have no acute onset of action but work 
(gradually) over a period of weeks to months. It is still largely unknown what under-
lying CNS mechanisms are involved in the slow onset of action of antidepressants. 
In the case of serotonergic antidepressants (SSRIs, SNRIs), a complex interaction 
between various 5-HT auto- and heteroreceptors as modulators of the SSRI-induced 
chronic increase in CNS serotonin plays a role [26]. Acute administration of SSRIs 
Inhibits somatodendritic 5-HT1A autoreceptors leading to inhibition of firing activity 
of serotonergic neurons and consequently dampened release of 5-HT in the fore-
brain, which, in some not yet understood way, contributes to the slow onset of action 
of SSRIs [27]. Desensitization of 5-HT1A autoreceptors after long-term administra-
tion might overcome the decrease in 5-HT release and subsequently would lead to 
high serotonin release [27]. Combining an SSRI and 5-HT1A-receptor antagonist 
might create a fast onset of action mechanism for antidepressant activity. The lack of 
availability of clinically approved selective 5-HT1A receptor antagonists led to studies 
using the mixed β-adrenoceptor/5-HT1A receptor antagonist pindolol together with 
various SSRIs in MDD patients [28]. In a placebo-controlled study, pindolol increased 
the antidepressant efficacy of fluoxetine, although no significant improvement in 
onset of action of the combination was found [29]. Pindolol is probably not the best 
tool to perform this kind of “onset of action” studies (pindolol is a relatively weak 
and not a full 5-HT1A receptor antagonist, and its beta-blocking activities induce side 
effects), but a study with a selective 5-HT1A-receptor antagonist did not find any 
difference either. It was postulated [30, 31] that two new multi-target antidepres-
sants, vilazodone (SSRI+ partial 5-HT1A receptor agonist) and vortioxetine (SSRI+5-
HT1A,1B,1D,7 receptor agonist and 5-HT3 receptor antagonist), might have an advantage 
over existing drugs in terms of efficacy and onset of antidepressant action, although 
clinical data thus far have not shown evidence for improving the onset of action [32, 
33]. It is evident that antidepressants that primarily act via monoaminergic neuro-
transmission all share the slow onset of action principle, and new molecules stem-
ming from this “classical” approach will not deliver fast onset of action compounds.
The finding that one single dose of intravenous ketamine produced rapid and sus-
tained antidepressant effects in depressed patients led to a new and exciting opening 
in this field [34]. Ketamine, an NMDA receptor antagonist and dissociative anesthetic, 
produces at low doses mild dissociative and psychotomimetic effects but also exerted 
rather unexpected antidepressant effects. One single dose of ketamine (0.5 mg/kg, 
intravenously by slow infusion) induced a rapid antidepressant effect (within hours) 
that lasted for 7 days [35]. Later studies have confirmed the fast antidepressant onset, 
even in TRD patients [6]. However, notwithstanding the apparent breakthrough 
in fast treatment of depression, the side effects of ketamine are still troublesome 
for general use. Recently (March 2019) a nasal preparation of the (S)-enantiomer 
(esketamine) received FDA approval after successful phase 3 trials. Moreover, 
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new approaches for fast-onset and effective antidepressants via modulation of the 
glutamatergic-NMDA system are now subject of intense research efforts [6, 36]. One 
may expect a new range of novel antidepressants with as main attribute a fast onset 
of action. Whether these new molecules have a higher efficacy (>50% of responding 
patients) or accordingly lead to less treatment resistance has to be awaited. Moreover, 
the side effect profile is likely quite different from the classical “monoaminergic” 
antidepressants. Only large number of well-treated patients will unravel the impact of 
these side effects. If only the onset of action is improved, the acceptance of such a new 
antidepressant will strongly depend on its side effect and safety profile.
One of the big items in the research and discovery of new and innovative 
antidepressants is the availability of animal models that are able to measure “onset 
of action,” “efficacy,” and “side effects” [37]. Onset of antidepressant action in an 
animal model is quite difficult to assess. Most animal depression tests are acute, in 
that they respond immediately to a dose of a certain antidepressant, e.g., forced 
swim test, tail suspension test, or DRL-72 sec paradigm. Animal depression models 
that do not respond acutely but only after chronic treatment of the classic antide-
pressants are rather scarce, although indispensable in the onset of action discovery. 
One of such models is the olfactory bulbectomized (OBX) rat [37, 38]. OBX leads to 
stable and lasting changes in behavior after removing the olfactory bulbs [39]. OBX 
leads within days after ablation to permanent changes in activity, basal body tem-
perature, heart rate and heart rate variability, and stress responsivity [39]. Increased 
locomotor activity in an open field is an often used simple parameter to measure the 
effects of antidepressants [38]. In an extensive review on available animal models, 
olfactory bulbectomy in rodents is considered superior to other animal models to 
detect onset of action of antidepressants [37], with a high sensitivity, specificity, 
and reliability and moderate ease to use the model. The model generated also the 
possibility to study effects of antidepressant treatment after cessation of treatment 
[40]. Chronic (14-day) treatment of imipramine (20 mg/kg) or escitalopram (5 
and 10 mg/kg) in OBX and sham-operated rats led to reduction of the hyperactiv-
ity in an open field by imipramine and escitalopram of the OBX rats, without 
effects in the control rats. This reduction in hyperactivity of OBX rats induced by 
chronic administration of antidepressants remained after cessation of treatment 
and lasted for 10 weeks after imipramine and 6 weeks after escitalopram cessation 
[40]. We concluded that the OBX-induced changes in the brain state (neuroplas-
ticity) are probably attenuated by chronic antidepressant administration and that 
these changes are only slowly returning to the previous OBX state. Pramipexole, a 
dopamine D3/D2 receptor agonist, used to treat Parkinson patients with additional 
antidepressant activity [41], indeed exerted antidepressant activity in the OBX 
model [42]. Pramipexole is also a psychostimulant and induces at higher doses 
enhanced locomotion itself, thereby interfering with the already enhanced activity 
of OBX rats. Remarkably, 1 week after cessation of treatment, pramipexole-treated 
OBX animals still were not hyperactive, similar to imipramine, thereby suggesting 
that antidepressant effects of drugs can be detected in the OBX model by using this 
post-cessation antidepressant-like effect [42]. Unpublished studies [43] found that 
3- and 7-day treatment with imipramine (10 mg/kg/day) normalized OBX-induced 
hyperactivity in the open field. One week after cessation of imipramine treatment, 
hyperactivity returned, suggesting that longer periods of treatment (14 days) are at 
least needed to lead to changes in brain neuroplasticity underlying the suppression 
of OBX-induced behavioral changes. In a complicated experimental design, ket-
amine (10 mg/kg, IP) was given to OBX and control rats 24 hours before testing in 
an open field but appeared ineffective [44]. The experimental design did not give a 
clear cue about the onset of action of antidepressant activity of ketamine, and more 
directed research into this avenue has to be initiated. Pandey et al. [45] found that 
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14-day but not 7-day treatment with ketamine (1 mg/kg/day) reduced hyperactivity 
induced by olfactory bulbectomy, although combination of escitalopram (10 mg/
kg/day) and ketamine (1 mg/kg/day) reduced hyperactivity at both 7 and 14 days. 
This may be an indication that ketamine in combination with an SSRI may speed up 
the onset of antidepressant action.
Recently the FDA has approved esketamine as a nasal spray for adjunctive 
therapy in treatment-resistant depression [46]. Esketamine is indicated for 
depressed patients that did not respond to at least two oral antidepressant mono-
therapies. It has to be given together with a newly initiated oral antidepressant 
under strict supervision of certified medical professionals, because of the potential 
serious adverse effects of esketamine. The launch of a successful potential anti-TRD 
medication might be a breakthrough in the treatment of depression.
4. Other applications for antidepressants
Apart from treatment of depression, antidepressants and particularly SSRIs and 
SNRIs are also widely used for treatment of various anxiety disorders, obsessive 
compulsive disorders, gambling disorders, posttraumatic stress disorder, and vari-
ous other psychiatric disorders, including alcohol use disorder.
In obsessive compulsive disorder, SSRIs are partially effective, but in general 
higher doses are needed, and onset of action (6–8 weeks) is slower than in depres-
sion. Because comorbidity of depression and anxiety is very high, it appeared that 
SSRIs could be used as a rational therapy for both disorders, although the disadvan-
tages of SSRIs in depression (side effects, onset of action, partial efficacy) are com-
parable in anxiety disorder treatment. In Chapter 4, Ballesta and coworkers review 
and discuss the role of antidepressants in alcohol use disorder (AUD). Because 
a strong relationship exists between major depression and AUD, the authors 
investigated the potential role of hippocampal plasticity and neurogenesis in both 
disorders. By integrating the knowledge of plasticity changes in the hippocampus 
and its role in both disorders, the authors try to implement shared mechanisms. It is 
clear that considerable research efforts, both preclinical and clinical, are needed to 
advance our possibilities to better treat both depression and alcohol use disorder.
5. Conclusion
The emergence of effective antidepressants in the 1960s and 1970s of the last 
century has led to an explosion of new and often unexpected new discoveries and 
clinical applications. The development of SSRIs after the serendipitous detection of 
the first tricyclic antidepressants has revolutionized the treatment of major depres-
sion but has also led to new treatments of various anxiety disorders, obsessive 
compulsive disorder, and various other psychiatric conditions.
Drug treatment always leads to side effects that can be quite cumbersome and 
often lead to drug discontinuation. Treatment resistance (TRD) is frequently occur-
ring in major depression, and a substantial part of depressed patients (about 30%) 
does not respond to any treatment. Recent developments (esketamine) promise 
new approaches in the treatment of TRD although side effects remain a big obstacle.
Research into new and better antidepressants remains urgent but depends pri-
marily on better understanding of the brain mechanisms involved in normal “mood” 
processing and understanding what is wrong in “depressed” brains. Animal models 
with high predictive and construct validity are urgently needed to help to discover 
these (dys)functional mechanisms and deliver new targets for better antidepressants.
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Abstract
Patients with alcohol use disorders (AUDs) are frequently treated with antidepres-
sant drugs (ADs), but clinical evidence of their efficacy is contradictory. Considering 
that ADs are thought to produce their therapeutic effects partially by increasing 
hippocampal plasticity and neurogenesis (HN), and that both AUDs and depression 
share a potential for the disruption of these neuroplastic processes, one could reason-
ably wonder whether the poor efficacy of AD treatment could be explained by the 
inability of these drugs to exert their proper action in patients suffering from AUD 
or depression. In order to further clarify this question, this chapter aims to examine 
available data regarding the effect of ADs on behavioral and HN alterations related to 
alcohol abstinence, as a key period in which the treatment would be implemented and 
in which their potential effects on alcohol-related problems remain under controversy.
Keywords: alcohol use disorders (AUDs), antidepressants (ADs),  
hippocampal neurogenesis (HN), depression, comorbidity, alcohol withdrawal
1. Introduction
AUD is a chronic relapsing brain disease characterized by the presence of various 
symptoms, such as physically hazardous alcohol drinking, tolerance, withdrawal, 
or craving related to alcohol consumption, whereas MD is a psychiatric disorder 
characterized by low mood, anhedonia, insomnia, low motivation, apathy, and 
feelings of guilt, among other symptoms [1]. Epidemiological studies have shown a 
strong relationship between alcohol use disorders (AUDs) and depression. Indeed, 
the prevalence of current or lifetime alcohol problems in depression is estimated 
around 16% and 30%, respectively [2].
Adult hippocampal neurogenesis (HN) is a complex multistep process by which 
neural progenitor cells (NPCs) divide throughout life and give rise to new functional 
neurons in restricted regions of the adult mammalian brain (Figure 1, and also 
described in [3]). The dentate gyrus of the hippocampus is one of the brain areas 
that respond to stimuli through multiple mechanisms that allow the proliferation, 
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1. Introduction
AUD is a chronic relapsing brain disease characterized by the presence of various 
symptoms, such as physically hazardous alcohol drinking, tolerance, withdrawal, 
or craving related to alcohol consumption, whereas MD is a psychiatric disorder 
characterized by low mood, anhedonia, insomnia, low motivation, apathy, and 
feelings of guilt, among other symptoms [1]. Epidemiological studies have shown a 
strong relationship between alcohol use disorders (AUDs) and depression. Indeed, 
the prevalence of current or lifetime alcohol problems in depression is estimated 
around 16% and 30%, respectively [2].
Adult hippocampal neurogenesis (HN) is a complex multistep process by which 
neural progenitor cells (NPCs) divide throughout life and give rise to new functional 
neurons in restricted regions of the adult mammalian brain (Figure 1, and also 
described in [3]). The dentate gyrus of the hippocampus is one of the brain areas 
that respond to stimuli through multiple mechanisms that allow the proliferation, 
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maturation, and integration of new generated neurons in this structure, an event that 
appears to regulate and improve impaired cognition and mood in various disorders [4]. 
Both AUDs and depression have shown to compromise HN processes [5, 6]. The HN 
theory of depression sustains that depression results from impaired adult HN, and, 
therefore, its restoration leads to recovery [7]. Direct causality of HN alterations in 
the pathogenesis of depression seems unlikely [8], but the clinical relevance of hip-
pocampal newly generated neurons in depression continues to be the object of study 
[9]. In addition, HN and plasticity processes have been proposed as a possible common 
neurobiological mechanism underlying alcohol withdrawal and depression [10]. In 
fact, HN has been proposed to significantly contribute to alcoholic pathology, although 
the mechanisms of alcohol-induced alterations in HN are not completely understood 
[6]. In this sense, there is strong evidence in animal models that alcoholic neuropathol-
ogy is at least partially due to an attenuation of adult HN induced by intoxication, a 
state that could be reversed by spontaneous reactive HN processes during abstinence 
[11]. In this regard, authors have proposed that while suppression of hippocampal 
neurogenic proliferation appears to be a factor of comorbid vulnerability, enhancing 
HN into the neural circuits affected by drug may contribute to recovery [12, 13].
Antidepressants (ADs), mainly selective serotonin reuptake inhibitors (SSRIs) 
and tricyclic antidepressants (TCAs), are the primary pharmacological treatment 
indicated for depression-diagnosed patients [14]. Concurrently, evidence of mono-
amine alterations in AUDs has encouraged the investigation of drugs that act on the 
serotonin system to treat alcohol abuse [15]. Only a few drugs with clear evidence 
but modest effects are approved for treatment of AUDs, as naltrexone and acam-
prosate, although given certain clinical circumstances, substance use disorders may 
require specific treatment; thus, off-label medications like ADs are also frequently 
prescribed, mainly in AUD depressed patients [16]. At first, the monoamine theory 
of depression is based on the fact that brain monoamine systems appear to regulate 
mood and traditional ADs, such as SSRI, and selectively increase monoamine signal-
ing in neural pathways related to mood regulation [17]. Later, at the beginning of the 
century, different results supported the hypothesis that ADs might affect mood by 
increasing adult HN [18]. At the same time, numerous studies have led to propose 
that ADs can influence HN by serotonin modulation and that HN may be related 
to AD effects (reviewed in [19]). In agreement, postmortem studies have reported 
Figure 1. 
Schematic representation of the stages of adult hippocampal neurogenesis in the subgranular zone of the 
dentate gyrus and the main immunolabeling techniques used in the cited studies.
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that ADs augment NPC numbers [20, 21] and restore mature hippocampal neural 
population and dentate gyrus volume of depressed patients [22, 23]. These human 
data reflect the neurogenic potential of ADs previously reported in animals [24]. In 
this respect, animal studies have led to suggest that, while not causally involved in 
the onset of depression, HN has been related to the ability of chronic monoaminergic 
ADs to achieve recovery [8]. Recent studies have reopened the debate about the 
functional implication of adult HN in humans (see [25]), highlighting the need to 
further study the generation of new neurons in the adult human hippocampus. This 
also implies to characterize the role of HN in depression and AUDs [4, 6] and the 
extent to which it participates in recovery in the treatment with ADs [26].
2. Alcohol use disorders and depression
Data from AUD patients have led to the proposal that the effective components of 
withdrawal, such as dysphoria and depressed mood, create a motivational drive that 
leads to compulsive ethanol drinking behavior even after long periods of abstinence [27]. 
Subsequent findings promoted the hypothesis that drugs of abuse elicit pronounced 
euphoria followed by a negative emotional state that can disrupt homeostasis, considered 
key to the etiology and maintenance of the pathophysiology of addiction [28].
2.1  Clinical and preclinical evidence of AUD contribution to depressive 
symptomatology
Authors have considered whether there may be a causal relationship between 
AUDs and depression and whether one of the disorders can lead to the appear-
ance of the other. Thus, numerous studies reveal ample evidence of the risk of 
depression resulting from AUDs [29]. Moreover, problematic patterns of alcohol 
consumption are related to depressive symptomatology, both in adult and ado-
lescent populations [30, 31]. In an attempt to simplify the complexities of the 
relation between AUDs and depression, a classification of depression as primary or 
secondary according to whether it developed before or after the onset of the AUD 
was proposed. The term independent (ID) was used for a depression that began 
before the onset of alcohol dependence or during sustained (at least 4 weeks) 
abstinence, while depressive syndromes occurring only during a period of active 
alcohol dependence were labeled as substance-induced (SID) [32]. However, some 
of the depressive symptoms classified as ID could actually be substance-induced, 
as SID appears not to be a stable diagnosis, with about one quarter of patients 
initially labeled with SID meeting criteria for ID within the next 12 months [33]. 
Thus, SID would be considered a self-limiting condition that would tend to remit 
with abstinence, while ID would require specific depression treatment [32]. After 
receiving treatment for alcohol consumption, those with SID would show better 
depression outcomes and reduce their drinking more than those with ID [32]. 
Also, and further supporting a causal role of alcohol consumption in depression, 
reducing its consumption would improve the outcomes for both types of depres-
sion [34]. In the same sense, some authors have proposed that reducing hazardous 
drinking can improve depressive symptoms, but continued hazardous use slows 
recovery for psychiatric patients [35].
2.2 Preclinical evidence of the contribution of alcohol to depressive-like behavior
Animal studies might overcome the limitations of the clinical studies, allowing 
to obtain not only correlative information but also contributing data that would 
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maturation, and integration of new generated neurons in this structure, an event that 
appears to regulate and improve impaired cognition and mood in various disorders [4]. 
Both AUDs and depression have shown to compromise HN processes [5, 6]. The HN 
theory of depression sustains that depression results from impaired adult HN, and, 
therefore, its restoration leads to recovery [7]. Direct causality of HN alterations in 
the pathogenesis of depression seems unlikely [8], but the clinical relevance of hip-
pocampal newly generated neurons in depression continues to be the object of study 
[9]. In addition, HN and plasticity processes have been proposed as a possible common 
neurobiological mechanism underlying alcohol withdrawal and depression [10]. In 
fact, HN has been proposed to significantly contribute to alcoholic pathology, although 
the mechanisms of alcohol-induced alterations in HN are not completely understood 
[6]. In this sense, there is strong evidence in animal models that alcoholic neuropathol-
ogy is at least partially due to an attenuation of adult HN induced by intoxication, a 
state that could be reversed by spontaneous reactive HN processes during abstinence 
[11]. In this regard, authors have proposed that while suppression of hippocampal 
neurogenic proliferation appears to be a factor of comorbid vulnerability, enhancing 
HN into the neural circuits affected by drug may contribute to recovery [12, 13].
Antidepressants (ADs), mainly selective serotonin reuptake inhibitors (SSRIs) 
and tricyclic antidepressants (TCAs), are the primary pharmacological treatment 
indicated for depression-diagnosed patients [14]. Concurrently, evidence of mono-
amine alterations in AUDs has encouraged the investigation of drugs that act on the 
serotonin system to treat alcohol abuse [15]. Only a few drugs with clear evidence 
but modest effects are approved for treatment of AUDs, as naltrexone and acam-
prosate, although given certain clinical circumstances, substance use disorders may 
require specific treatment; thus, off-label medications like ADs are also frequently 
prescribed, mainly in AUD depressed patients [16]. At first, the monoamine theory 
of depression is based on the fact that brain monoamine systems appear to regulate 
mood and traditional ADs, such as SSRI, and selectively increase monoamine signal-
ing in neural pathways related to mood regulation [17]. Later, at the beginning of the 
century, different results supported the hypothesis that ADs might affect mood by 
increasing adult HN [18]. At the same time, numerous studies have led to propose 
that ADs can influence HN by serotonin modulation and that HN may be related 
to AD effects (reviewed in [19]). In agreement, postmortem studies have reported 
Figure 1. 
Schematic representation of the stages of adult hippocampal neurogenesis in the subgranular zone of the 
dentate gyrus and the main immunolabeling techniques used in the cited studies.
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the onset of depression, HN has been related to the ability of chronic monoaminergic 
ADs to achieve recovery [8]. Recent studies have reopened the debate about the 
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2. Alcohol use disorders and depression
Data from AUD patients have led to the proposal that the effective components of 
withdrawal, such as dysphoria and depressed mood, create a motivational drive that 
leads to compulsive ethanol drinking behavior even after long periods of abstinence [27]. 
Subsequent findings promoted the hypothesis that drugs of abuse elicit pronounced 
euphoria followed by a negative emotional state that can disrupt homeostasis, considered 
key to the etiology and maintenance of the pathophysiology of addiction [28].
2.1  Clinical and preclinical evidence of AUD contribution to depressive 
symptomatology
Authors have considered whether there may be a causal relationship between 
AUDs and depression and whether one of the disorders can lead to the appear-
ance of the other. Thus, numerous studies reveal ample evidence of the risk of 
depression resulting from AUDs [29]. Moreover, problematic patterns of alcohol 
consumption are related to depressive symptomatology, both in adult and ado-
lescent populations [30, 31]. In an attempt to simplify the complexities of the 
relation between AUDs and depression, a classification of depression as primary or 
secondary according to whether it developed before or after the onset of the AUD 
was proposed. The term independent (ID) was used for a depression that began 
before the onset of alcohol dependence or during sustained (at least 4 weeks) 
abstinence, while depressive syndromes occurring only during a period of active 
alcohol dependence were labeled as substance-induced (SID) [32]. However, some 
of the depressive symptoms classified as ID could actually be substance-induced, 
as SID appears not to be a stable diagnosis, with about one quarter of patients 
initially labeled with SID meeting criteria for ID within the next 12 months [33]. 
Thus, SID would be considered a self-limiting condition that would tend to remit 
with abstinence, while ID would require specific depression treatment [32]. After 
receiving treatment for alcohol consumption, those with SID would show better 
depression outcomes and reduce their drinking more than those with ID [32]. 
Also, and further supporting a causal role of alcohol consumption in depression, 
reducing its consumption would improve the outcomes for both types of depres-
sion [34]. In the same sense, some authors have proposed that reducing hazardous 
drinking can improve depressive symptoms, but continued hazardous use slows 
recovery for psychiatric patients [35].
2.2 Preclinical evidence of the contribution of alcohol to depressive-like behavior
Animal studies might overcome the limitations of the clinical studies, allowing 
to obtain not only correlative information but also contributing data that would 
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allow a larger approach to the possible underlying causes in the relation of the AUD 
and depression. Several preclinical studies have assessed behavioral alterations 
during acute withdrawal and/or protracted abstinence in different animal models 
of alcohol abuse [36–47]. Studies used rodents as experimental animals, and the 
majority used the AUD model of chronic intermittent ethanol (CIE) vapor expo-
sure. Behavioral analysis was carried out from a few hours (less than 24 hours) to 
several days or weeks after the last alcohol consumption, using the forced swim-
ming test (FST) the most frequently used paradigm for this purpose. FST allows 
detecting responses toward an inescapable stress in animals based on the measure-
ment of the time they remain immobile rather than displaying active strategies, 
akin to responses that would be impaired in depression. This response has been 
commonly described in the literature as depressive-like behavior. Affective altera-
tions induced by alcohol were generally detected once alcohol exposure ceased, 
regardless of the animal model used, with few exceptions. It is interesting to 
note that studies evaluating both acute and chronic abstinence found occurrence 
of depressive-like behavior in both experimental periods although mostly after 
prolonged abstinence, which may indicate that the negative affective state as a 
consequence of abstinence, especially when maintained for prolonged periods, 
might be a risk factor for displaying depressive-like behavior, analogous to the way 
in which depression manifests itself in abstinent AUD patients.
2.3 Depression contributes to the risk of alcohol relapse
As previously mentioned, a negative affective state is not only a consequence of 
consumption but also could represent a maintenance factor for the addiction cycle 
[28]. In coherence, the “self-medication” theory postulates that the desire to avoid 
or alleviate preexisting or abstinence-related aversive states is a determining fac-
tor of excessive drug use and relapse [48]. Relapse is one of the most complicated 
components of drug addiction and involves a complex interaction of drug-associated 
cues that respond to multiple biological, psychiatric, psychological, and psychosocial 
factors which may precipitate the restoration of consumption [49, 50]. Therefore, 
one of the main goals in treating substance abuse is to preserve abstinence.
2.4  Clinical evidence of depressive symptomatology contributing  
to the risk of alcohol relapse
Clinical data strongly support the relevance of negative emotionality in protracted 
abstinence and relapse. Thus, for example, a higher prevalence of depressed mood has 
been observed in AUD patients who relapsed [51]. Depression-related low motiva-
tion has been shown to precipitate alcohol relapse, while improvements contributed 
to greater abstinence [52–55]. In fact, those studies have emphasized the need to treat 
depression to preserve abstinence and improve outcome of patients with AUD. We men-
tioned before that the AUD can contribute to an ID or a SID. Thus, some authors wonder 
whether transient symptomatology (SID) would affect consumption in the same way as 
the observed ID in prolonged abstinence. In this sense, it has been suggested that while 
affective dysregulation in protracted abstinence is likely to be of immediate relevance for 
relapse to excessive alcohol use, the link between the early withdrawal phenomena and 
subsequent affective alterations remains unclear. However, other authors have concluded 
that both categories should be taken into account as factors that would precipitate 
relapse. Specifically, SID has been associated with a shorter time for the first alcohol con-
sumption after discharge, while ID, in addition, predicted relapse to alcohol dependence. 
Interestingly, ID prior to the AUD did not predict outcomes for patients [56].
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2.5  Preclinical evidence of depressive-like behavior contributing  
to the risk of alcohol relapse
Results from clinical studies underline the need to understand possible underly-
ing factors that contribute to the mutual negative influence of both pathologies. In 
this sense, animal models of AUD and depression offer the possibility of elucidating 
potential factors involved in the development of dual disorders [57]. Despite the 
prevalent comorbidity between depression and AUDs, direct evidence of causal-
ity of co-occurrence of the two pathologies is still scarce. Thus, Riga et al. [58] 
used a combination of models of depression and AUD through social defeat and 
alcohol self-administration and reported that a persistent depressive-like state led 
to profound alcohol reward-related changes, exaggerating the incentive salience of 
alcohol and facilitating cue-induced relapse to alcohol seeking. In addition, Lee et al. 
[47] reported higher alcohol self-administration behavior in mice which exhibited 
depressive-like behavior in prolonged abstinence as consequence of alcohol self-
administration. It is interesting to note that this condition only occurred in animals 
that were exposed to alcohol during their adolescence and not in those in which the 
first exposure took place during adulthood, and that did not show alcohol-related 
affective alterations. Animal studies would show that affective alterations that 
persist in prolonged abstinence, regardless of whether they were related or not 
with alcohol exposure, would increase self-administration behavior under alcohol 
re-exposition.
3. Alcohol use disorders and hippocampal neurogenesis deterioration
Years ago, the proposal arose that alcohol abuse might exert its negative effect 
in the human brain through an induction of neuronal loss on the hippocampus. In 
agreement, animal models of chronic alcohol exposure have shown consistently that 
alcohol is toxic to hippocampal neurons, inducing cell loss. Subsequent studies have 
led to suggest that alcohol may result in hippocampal pathology and deterioration 
through effects on adult HN (see [6]).
3.1  Clinical evidence of AUDs contributing to hippocampal  
neurogenesis deterioration
The lack of techniques to assess adult HN in vivo in AUD patients limits the 
available information in this regard essentially to postmortem or neuroimaging 
studies. To date, we have only found one study that has shown that alcohol would 
have a negative effect on HN in humans [59]. Authors reported reduced numbers 
of three biomarkers representing different stages of the HN process: Ki67, as 
marker for cell proliferation, the sex determining region Y-box (Sox2) as stem/
progenitor cell marker, and doublecortin (DCX) as marker of neural matura-
tion in the dentate gyrus in subjects with ongoing alcohol abuse. These results 
converge with previous findings in human with a history of drug abuse [60]. 
Otherwise, neuroimaging studies allow the detection that alcohol abuse could 
also impair hippocampal volume. Indeed, some studies have revealed decreases in 
hippocampal volume in AUD patients, although these changes have been shown to 
revert with abstinence (reviewed in [61]). There is also evidence of impairment in 
hippocampus-related functions as consequence of problematic alcohol consump-
tion, effects that, similarly to those found in volumetric studies, could improve 
with abstinence [62].
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led to suggest that alcohol may result in hippocampal pathology and deterioration 
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converge with previous findings in human with a history of drug abuse [60]. 
Otherwise, neuroimaging studies allow the detection that alcohol abuse could 
also impair hippocampal volume. Indeed, some studies have revealed decreases in 
hippocampal volume in AUD patients, although these changes have been shown to 
revert with abstinence (reviewed in [61]). There is also evidence of impairment in 
hippocampus-related functions as consequence of problematic alcohol consump-
tion, effects that, similarly to those found in volumetric studies, could improve 
with abstinence [62].
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3.2  Preclinical evidence of alcohol contributing to hippocampal  
neurogenesis deterioration
Animal studies are useful to compensate for the limited clinical evidence in AUD 
patients. In fact, the most consistent evidence of alcohol-induced hippocampal impair-
ment due to, in part, its action on HN comes from preclinical studies. In addition, the 
different immunolabeling techniques allow us to differentiate the stages of adult animal 
HN, as proliferation, maturation, migration, and survival of newly generated cells. 
Obtaining samples throughout different stages offers detailed information on how these 
processes are altered along the addictive cycle, which constitutes a great advantage 
over the limitations of postmortem studies in humans. The majority of in vivo stud-
ies have shown that alcohol intoxication leads to an overall decrease in HN through 
alcohol’s effects on cell proliferation and survival [63], while those HN parameters 
show heterogeneous results when assessed throughout abstinence. Several animal 
studies have evaluated HN parameters along acute withdrawal and/or protracted 
abstinence in different AUD models. Studies mainly analyzed parameters of HN at 
different times throughout abstinence and reported increases, decreases, and mixed 
results in HN-related parameters [64–79]. Studies were mainly in rodents (except [72], 
done in nonhuman primates). A large part of the studies used a 4-day binge model or 
self-administration protocols, whereas few authors used the CIE vapor exposure model. 
Different immunolabeling techniques have been used to assess HN in animals, mainly 
the thymidine analogue bromodeoxyuridine (BrdU), which is incorporated into divid-
ing cells and allows monitoring of newly generated neurons in the adult brain. Main 
relevant aspects of results from those studies are analyzed in detail in the conclusion.
3.3  Hippocampal neurogenesis deterioration contributes to the risk  
of alcohol relapse
Hippocampus is essential in consolidation of stimuli previously paired with 
drug intake, and authors have proposed that alcohol produces strong deficits 
in hippocampus-dependent learning and memory and attenuates hippocampal 
plasticity during withdrawal, which may motivate attempts to self-medicate result-
ing in relapse and maintenance of drug use [80]. In this sense, one way by which 
impaired HN could contribute to addiction would be by disrupting learning and 
memory and by inducing negative affective states, both factors increasing suscepti-
bility to relapse [81]. On the other hand, research during the last decade has shown 
that it is possible to disrupt alcohol-induced cues and that this has a lasting impact 
in reducing the tendency to seek drugs and to relapse [82]. In this regard, authors 
have suggested that although there are a host of plastic changes that occur with 
abstinence, one way that the hippocampus may recover in abstinence is through the 
repopulation of the dentate gyrus by adult HN [6].
3.4  Clinical evidence of hippocampal neurogenesis deterioration  
contributes to the risk of alcohol relapse
In the same way as in the previous sections, human studies provide indirect 
indicators of the role of HN, such as the volume and functionality of the hippocam-
pus. In this regard, clinical studies found that deficits in hippocampal volume in 
AUD patients compared with healthy controls normalize over an abstinence period 
of 2 weeks [83] and that hippocampal volume did not constitute a predictive factor 
for relapse risk in abstinent alcoholics [84]. On the other hand, it has been observed 
that the hippocampal-dependent functions could continue to be altered even in 
prolonged abstinence [62], which could be a factor that, as other authors propose, 
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would alter cognitive aspects linked to the risk of relapse [80]. Information from 
clinical studies shows that the course of the AUD would be related to the func-
tionality of the hippocampus and not so much with alterations in its structure. 
Unfortunately, like the previous section, we are faced with a lack of clinical evi-
dence in this regard, since we do not have information on the role that newly gener-
ated neurons in the hippocampus would play on the learning and memory processes 
involved in prevent relapse.
3.5  Preclinical evidence of hippocampal neurogenesis deterioration  
contributes to the risk of alcohol relapse
Numerous animal studies have led to suggest that low neurogenic states 
could regulate the addictive behavior, assuming a factor of addiction or comor-
bid vulnerability [12]. Specifically, animal models of drug addiction studies 
have led to propose that adult HN appears to be important for the maintenance 
of hippocampal neuroplasticity, such that reducing HN during abstinence may 
increase the vulnerability to relapse, while enhancing HN during abstinence 
may help reduce the risk of relapse [22]. Among the studies cited that assessed 
HN parameters, only one study [78] analyzed the levels of alcohol consump-
tion after the period of abstinence. Thus, they reported augmented alcohol 
self-administration after 4 weeks of abstinence in animals that showed reduced 
HN at the end of the experiment as consequence of a combination of self-
administration and vapor exposures to alcohol (dependent animals) compared 
to animals that showed no reductions in HN who did not receive exposure to 
vaporized alcohol (nondependent animals). Some results from [78] suggest 
that the observed reactive HN effect does not have an implication in recovery. 
On the contrary, animals that showed this reactive effect and lower levels of 
survival of newly generated neurons ended up showing higher alcohol con-
sumption during relapse. Main implications of these findings are analyzed in 
the conclusion.
4.  AD treatment in alcohol use disorders, depression,  
and hippocampal neurogenesis
Several studies have led to the suggestion that reversing depressive symptom-
atology [54] and HN deterioration [21] could be a therapeutical option in cases of 
comorbidity between AUDs and depression. Given the potential of ADs to improve 
affective symptoms and promote HN, it is reasonable to assume that such treatment 
would benefit AUD patients. The following sections attempt to clarify these aspects.
4.1  Clinical evidence of antidepressant treatment improves depressive 
symptomatology and hippocampal neurogenesis deterioration
Meta-analysis and reviews that integrate results of clinical studies in which 
patients with AUD and depression were treated with ADs show drug-dependent 
and inconclusive results. Some findings showed that SSRIs adequately treat 
depressive symptomatology in individuals with AUD and depression [85–87], 
while others showed that SSRIs were not more effective than placebo in treating 
comorbid patients [88, 89]. In relation, it has also been seen that SSRIs would not 
show greater effects than TCAs [90]. In fact, results from different studies using 
TCAs seem to converge in its effectiveness in alleviating depressive symptom-
atology [88, 91]. This may present differences in the response to a treatment for 
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administration and vapor exposures to alcohol (dependent animals) compared 
to animals that showed no reductions in HN who did not receive exposure to 
vaporized alcohol (nondependent animals). Some results from [78] suggest 
that the observed reactive HN effect does not have an implication in recovery. 
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4.  AD treatment in alcohol use disorders, depression,  
and hippocampal neurogenesis
Several studies have led to the suggestion that reversing depressive symptom-
atology [54] and HN deterioration [21] could be a therapeutical option in cases of 
comorbidity between AUDs and depression. Given the potential of ADs to improve 
affective symptoms and promote HN, it is reasonable to assume that such treatment 
would benefit AUD patients. The following sections attempt to clarify these aspects.
4.1  Clinical evidence of antidepressant treatment improves depressive 
symptomatology and hippocampal neurogenesis deterioration
Meta-analysis and reviews that integrate results of clinical studies in which 
patients with AUD and depression were treated with ADs show drug-dependent 
and inconclusive results. Some findings showed that SSRIs adequately treat 
depressive symptomatology in individuals with AUD and depression [85–87], 
while others showed that SSRIs were not more effective than placebo in treating 
comorbid patients [88, 89]. In relation, it has also been seen that SSRIs would not 
show greater effects than TCAs [90]. In fact, results from different studies using 
TCAs seem to converge in its effectiveness in alleviating depressive symptom-
atology [88, 91]. This may present differences in the response to a treatment for 
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depression in alcohol-dependent participants depending on the different types of 
depression, as a stronger effect of ADs was found in ID than in SID patients [32]. 
The most recent meta-analysis available concerning the efficacy of AD treatment 
in these patients shows a modest effect in some outcomes of depression [92]. 
However, most authors point out the need for more studies with similar outcome 
measures, well-defined sample designs, adequate doses, and duration of treat-
ment so that the integration of studies can reach conclusions with a high quality of 
evidence [87, 90, 92], and some of them emphasize the need to evaluate possible 
alternative ADs, as, for example, nonselective or partial agonist-reuptake inhibi-
tors [93, 94]. On the other hand, as seen in the introduction, ADs have shown to 
potentially increase HN in depressed patients [20, 21]. Unfortunately, no evidence 
of AD-related HN effect has been described in AUD patients.
4.2  Preclinical evidence of antidepressant treatment improves  
depressive-like behavior and hippocampal neurogenesis deterioration  
in alcohol exposure and abstinence
Studies in animals have suggested that the ability of AD treatment to affect HN 
would be linked to its behavioral therapeutic effects [8]. In fact, authors reported that 
increasing HN has been demonstrated to be necessary and sufficient to reduce depres-
sive-like behavior in animals [95]. On the contrary, other authors have concluded 
that, although ADs promote HN, this would not be a critical event for their mood-rec-
tifying actions [96]. In the same direction, authors have proposed that the therapeutic 
effect of the AD would not be determined exclusively by an increase in the number of 
newly generated neurons but rather in the way in which those neurons are function-
ally incorporated into hippocampal preexisting circuits that would be linked to recov-
ery [97]. Few animal studies evaluated the efficacy of an AD treatment (desipramine, 
imipramine, and amitifadine) in a model of alcohol exposure. Studies from Getachew 
et al. [36, 43] found that subchronic desipramine and imipramine treatment reversed 
depression-like behavior and anxiety in rodents under acute withdrawal conditions. 
Similarly, Warnock et al. [39] reported that two different doses of acute amitifadine 
reversed the abstinence-induced increased immobility in the FST. Finally, Stevenson 
et al. [37] reported that subchronic desipramine reverted depression-like behavior 
and restored HN parameters, both aspects impaired under protracted abstinence 
conditions in mice. Similarly, other studies have tested the efficacy of AD-like drugs 
as 7,8-DHF, a trkB agonist [40]; trichostatin A, a histone deacetylase inhibitor [76]; 
rolipram, a phosphodiesterase-4 inhibitor [45]; or ketamine, a N-methyl-D-aspartate 
receptor antagonist [42, 46], reporting that those treatments also restored the HN 
parameters and/or the behavioral alterations impaired by the exposure and absti-
nence to alcohol. In addition, non-pharmacological conditions, as wheel running 
or natural extracts, induced similar patterns of recovery in HN parameters [65, 77] 
and in depressive-like behavior [45, 50] in rodents exposed and abstinent of alcohol. 
This data, in conjunction with previous studies that used ADs, would suggest that if 
a treatment had protective effects on the NH function, it could also reflect its thera-
peutic effect on affective disturbances in alcohol exposed animals. Nevertheless, the 
causality of this relationship needs to be further elucidated. Figure 2 illustrates the 
possible state and role of HN during alcohol withdrawal.
4.3  Clinical evidence of antidepressant treatment improves depressive  
and alcohol use disorder outcome
Although ADs are not among the first-line treatment options in AUD, they are 
among the additional alternative treatments available, mainly when comorbid 
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conditions are present [16]. In this regard, authors have proposed that AD treat-
ment could ameliorate alcohol consumption [98], possibly by improving depressive 
symptoms [99]. Some of the aforementioned studies and meta-analysis evaluated 
alcohol-related outcomes in AUD depressed patients [87, 90, 92], showing a modest 
or no efficacy of AD treatment in alleviating some aspects linked to alcohol con-
sumption. Recent conclusions show that ADs increased the number of participants 
abstaining during the trials and reduced the number of drinks per drinking day, 
while no differences were reported between ADs and placebo in other relevant out-
comes of the AUD [92]. In addition to the mentioned low overall effectiveness, it is 
important to mention that some studies reported even poorer drinking outcomes in 
AUD patients treated with SSRIs compared to those treated with placebo [100–102]. 
In this line, studies have reported clinical cases where treatment with SSRIs appears 
to be the cause of increased frequency of intoxication by alcohol and new onset of 
alcohol-related problems [103–105]. Finally, patients who actively drink suffering of 
comorbid anxiety and AUD have also shown that they may increase alcohol con-
sumption under treatment with SSRIs [106].
4.4 Preclinical evidence of antidepressant treatment improves alcohol relapse
Preclinical data concerning the effectiveness of pharmacological treatments 
in AUDs is still scarce [107]. Animal studies that evaluate the effect of different 
AD treatments on preventing alcohol consumption report reduction in alcohol 
intake after an acute drug dose or under short-term relapse conditions [108]. 
Nonetheless, taking in mind that the evaluation of the effectiveness of conven-
tional AD treatment should be done considering the delay in its therapeutic 
effects, studies should go beyond short-term evaluations, assessing long-term 
Figure 2. 
(a) Schematic representation of the adult HN along alcohol withdrawal and abstinence. Spontaneous burst in 
cell proliferation is followed by a lower survivability and aberrant patterns of cell migration and integration of 
the newly generated neurons which could contribute to vulnerability related circuitry. (b) Exogenously induced 
cell proliferation (by physical exercise or proneurogenic treatment as ADs) could prevent the consolidation 
of neural circuitry involved in vulnerability, promoting survivability and integration of the newly generated 
neurons into neural pathways of recovery.
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consequences of treatment in animal models that better mimic AUD patient 
conditions [109]. Thus, unlike studies using acute treatments, authors that 
evaluated chronic and subchronic escitalopram, sertraline, paroxetine, fluox-
etine (SSRIs), and duloxetine, dual serotonin/norepinephrine reuptake inhibitor 
(SNRI) treatments found that, along the treatment period, animals showed 
lower alcohol intake levels, but cessation of treatment produced a restoration of 
basal alcohol consumption [110–112]. Ho et al. [110] also found an augmentation 
in alcohol intake in depressed animals once treatment with escitalopram ceased. 
Interestingly, authors also found the same effect in animals under combina-
tion of AD (escitalopram) and anti-relapse (acamprosate) treatments. Related 
to that, subchronic treatment with different ADs (SSRIs and SNRIs) has been 
demonstrated to augment alcohol consumption in animal models of alcohol 
deprivation, which were treated along abstinence and re-exposed to alcohol self-
administration once AD treatment ended [113, 114].
5. Conclusions
Translating evidence from preclinical studies to clinical practice still creates 
a major challenge in development of new pharmacological treatments in AUDs. 
The first thing we must point out is the lack of animal studies that have evaluated 
the effectiveness of the AD treatment in alcohol exposure and abstinence. In this 
sense, it is important to highlight the numerous studies in animals that evaluate the 
alcohol exposure and abstinence impact on affective and HN parameters compared 
to the scarce studies that try to reverse such effects by testing appropriate ADs. In 
addition, strong criteria are needed when evaluating treatments in AUD animal 
models, highlighting the use of self-administration procedures and the evaluation 
of dependence by observing abstinence and relapse behavior. In this sense, animal 
studies evaluating HN alterations were mainly used as short periods (4 days) of 
forced alcohol exposition, while prolonged self-administration or CIE models, 
which better represent important aspects of alcohol consumption patterns in AUD 
patients, were used to a lesser extent.
One of the most direct methodological limitations when comparing clinical and 
preclinical studies is determined by the period in which the AD treatment begins. 
Preclinical studies would indicate that animals can display different affective 
responses to ADs according to the moment it is administered. In addition, AD ces-
sation could have negative repercussions in alcohol consumption and relapse. While 
these effects should be further clarified in future studies, clinical trials should take 
these relevant aspects into account.
The debate about the implication of the new neurons generated in the hippo-
campus as a consequence of alcohol abstinence continues to be an object of interest. 
Despite alcohol-induced HN impairments that mainly persist along abstinence, 
some studies have shown increases in parameters of neural proliferation in animals 
mainly along early withdrawal periods. First, the possible role of this HN re-
establishment effect as factor of recovery was considered, but later studies would 
even point to opposing hypotheses. In this regard, other findings led to the question 
whether neurons born during this reactive neurogenic process survive or properly 
integrate into the existing hippocampal circuitry to provide beneficial effects on 
hippocampal function and recovery. An early increase in neuronal proliferation 
induced by abstinence, followed by a reduction in survival in prolonged abstinence, 
appears to result in an increase in alcohol self-administration. Thus, this apparent 
AD-induced dual role of HN and the consequent changes in addictive behavior 
should be elucidated.
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To resume, preclinical evidence strongly supports that alcohol consumption 
and abstinence lead to negative affective states and alterations in HN, some of 
which may persist in prolonged abstinence. Although affective alterations related to 
alcohol have been evaluated, there is limited data available concerning the alcohol-
induced HN deterioration in clinical patients. Both alcohol-induced depression 
and changes in HN could be relevant to promote relapse, exacerbating the addic-
tive cycle, although additional studies should clarify this complex interaction. 
Conventional ADs have been proposed to alleviate affective alterations possibly 
by promoting HN; thus AUD depressed patients could benefit from its effects. 
Unfortunately, clinical trials still face several limitations in order to draw reli-
able conclusions in this regard. Moreover, preclinical studies should bear in mind 
important methodological aspects onward when translating information regarding 
the efficacy of AD treatment into AUD patients.
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The term resistant points out a clinical phenomenon in which there is a lack of 
response to one or more therapeutic interventions. Resistance to major depressive 
disorder treatment causes distress to patients and their relatives, and increases 
the number of hospital admissions, outpatient consultations, use of psychoactive 
drugs, and treatment costs. Despite its serious medical and psychosocial medi-
cal implications, the definition of treatment resistant depression continues to be 
ambiguous and controversial. The lack of an agreement on definition, as well as the 
research on the subject being difficult, limits the practical knowledge on the best 
treatment options for groups of treatment resistant depression (TRD) patients. We 
review the concept and definitions of treatment resistant depression as well as the 
medical literature on different treatment methods studied and comparative studies. 
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1. Introduction
The term “resistant” is widely employed in medical practice to point out a 
clinical phenomenon in which there is a lack of response to one or more therapeu-
tic interventions. The presence of treatment resistance implies a specific series 
of clinical interventions, typically multidisciplinary, and focuses on solving or 
minimizing a medical problem. Resistance to major depressive disorder treatment, 
but also to other depressive disorders, such as dysthymia and bipolar depression, 
causes distress to patients and their relatives, and increases the number of hospital 
admissions, outpatient consultations, the use of psychoactive drugs, and treat-
ment costs up to six times [1]. The definition of treatment resistant depression 
(TRD) continues to be ambiguous and controversial despite its serious medical and 
psychosocial implications. In medical literature, we can find more than 10 different 
definitions [2]. Many authors have published staging systems with their own defini-
tions, descriptions, and characteristics on TRD [3–7]. The most accepted definition 
is a lack of response to two different pharmacological classes of antidepressants 
[8]. However, this definition may seem simplistic today as published treatment 
results on TRD patients emerge. The lack of an agreed TRD definition as well as the 
difficulties to do research on the subject limit our practical knowledge on the best 
treatment options for groups of TRD patients.
We review the concept and definitions of TRD. We also review the medical 
literature on different treatment methods studied as well as comparative studies. 
Finally, we review some relevant emerging neurobiological data.
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1. Introduction
The term “resistant” is widely employed in medical practice to point out a 
clinical phenomenon in which there is a lack of response to one or more therapeu-
tic interventions. The presence of treatment resistance implies a specific series 
of clinical interventions, typically multidisciplinary, and focuses on solving or 
minimizing a medical problem. Resistance to major depressive disorder treatment, 
but also to other depressive disorders, such as dysthymia and bipolar depression, 
causes distress to patients and their relatives, and increases the number of hospital 
admissions, outpatient consultations, the use of psychoactive drugs, and treat-
ment costs up to six times [1]. The definition of treatment resistant depression 
(TRD) continues to be ambiguous and controversial despite its serious medical and 
psychosocial implications. In medical literature, we can find more than 10 different 
definitions [2]. Many authors have published staging systems with their own defini-
tions, descriptions, and characteristics on TRD [3–7]. The most accepted definition 
is a lack of response to two different pharmacological classes of antidepressants 
[8]. However, this definition may seem simplistic today as published treatment 
results on TRD patients emerge. The lack of an agreed TRD definition as well as the 
difficulties to do research on the subject limit our practical knowledge on the best 
treatment options for groups of TRD patients.
We review the concept and definitions of TRD. We also review the medical 
literature on different treatment methods studied as well as comparative studies. 
Finally, we review some relevant emerging neurobiological data.
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2. Treatment resistance depression (TRD)
2.1 The concept of resistant depression
Although this phenomenon had already been described, many authors have intro-
duced the concept of TRD since 1974 [9, 10]. This concept arises at a time when there 
were only tricyclic, tetracyclic, and monoamine-oxidase inhibitors (MAOIs) antide-
pressants available. In spite of its importance, the definition of treatment resistance 
regarding major depression continues to be a wide and inconsistent notion. A review 
of the literature identifies a range of definitions for TRD that go from non-response 
to a single antidepressant (for 4 or more weeks) to lack of response to different classes 
of antidepressants and electroconvulsive therapy (ECT) [2]. Treatment should be 
appropriate in dose and duration [2, 11–13], and patients must have full compliance 
to it [13] to consider a patient as resistant to treatment. There is no consensus on the 
number of treatments and when these are indicators of resistance.
A dichotomic denomination has been proposed for resistant depression, viz. 
an absolute and a relative. Absolute resistance is an inappropriate anti-depressive 
response toward a treatment given for an appropriate period of time at the maxi-
mum non-toxic dose. On the other hand, relative resistance to treatment is defined 
when this is given at a suboptimal dose or duration [5, 10, 14]. The terms “chronic,” 
“refractory,” and “difficult-to-treat depression” have been employed as synonyms 
in the absence of a nonspecific number of clinical trials for one or more antidepres-
sants. Treatment refractory depression refers to major depression that does not 
respond to multiple sequential treatments. There is no clear difference between 
treatment resistant depression and refractory depression [5, 8, 11]. Chronicity, 
however, refers to a pathological clinical phenomenon that lasts for 2 or more years. 
There is no consensus on depressive symptom severity to consider it as resistant. It 
has been suggested that a score of 16 or more on the Hamilton depression 17-item 
scale (HAM-D) is enough to confirm the diagnosis. However, patients with persis-
tent mild or moderate depressive symptoms may have a worse prognosis than those 
in remission [15]. The definition of Berlim and Turecki [2], which considers TRD 
as an episode of major depression that has not improved after two proper attempts 
with different classes of antidepressants, prevails today. The European Medicine 
Agency (EMA), on a TRD definition review, considers it as a clinically relevant 
major depression that has not benefited from at least two appropriate attempts of 
treatment with at least two antidepressants with a different action mechanism [16]. 
The definition which considers TRD as an episode of major depression that has 
not improved after two proper attempts with different classes of antidepressants 
[2] seems to be backed up by the STAR*D study, which shows that improvement 
chances diminish after the second treatment failure [17, 18]. Treatment resistance 
to pharmacologic treatment seems to move on a continuum that ranges from total 
response to total resistance to therapeutic intervention and not as an all-or-nothing 
phenomenon [5, 19, 20]. However, no definition has been investigated regarding 
validity and predictability [5, 21]. Inconsistencies on the definition not only give 
rise to difficulties at estimating its prevalence [17, 22] but can also delay research of 
the most efficient treatment schemes.
2.2 Prevalence of resistant depression
In spite of pharmacological treatment advances in major depression, the final 
objective of achieving a sustained improvement continues to be insufficient [23]. 
It is estimated that about only 30–40% of patients achieve remission after the first 




with escitalopram, only 37% achieved remission [18]. Even after an appropriate 
sequence of treatments, 10–20% of the patients with major depression continue 
with significant symptoms for 2 years or more [24, 25]. The STAR*D study 
(sequenced treatment alternatives to relieve depression study) showed that accu-
mulated remission after four treatment trials with antidepressants for 14 months 
was 67% [26]. Patients with chronic depression seem to have less opportunity for 
recovery [27] and tend to be more resistant to treatment [1, 28]. TRD is also associ-
ated to longer time of treatment and increased costs [29].
2.3  Antidepressant treatment resistance assessment scales and stratification 
systems
2.3.1 Antidepressant treatment assessment scales
From the multiple published assessment scales, three of them stand out in litera-
ture: the Antidepressant Treatment History Form [30], the Harvard Antidepressant 
Treatment History [31], and the Massachusetts General Hospital Antidepressant 
Treatment Response Questionnaire [6]. The clinician performs the former two; the 
latter is performed by the patient.
The Antidepressant Treatment History Form (ATHF; 1990; revised 1999) was 
originally designed to assess the efficacy of antidepressant treatment before ECT 
[30]. The scale has five treatment levels, which go from 0 (no treatment) to 5 (high 
antidepressant doses plus lithium or triiodothyronine (T3) for at least 4 weeks, 
including antipsychotics in patients with depression and psychotic symptoms. The 
scale has been modified and recently digitalized [32]. This scale has the disadvan-
tage of not including pharmacological combination strategies or preferences on 
switching treatment [33]. The Antidepressant Treatment History Form has been 
empirically validated with the monitoring of prospective treatment [8, 33–35]. The 
original ATHF version has a good inter-rater reliability [3], and the digitalized ver-
sion has an excellent inter-rater reliability as well, with another evaluator [32].
The Harvard Antidepressant Treatment History (HATH) allows to systemati-
cally assess the dose and duration of previous antidepressant medication trials. 
The patient identifies all the antidepressants taken from a list of all available once, 
a series of systematic questions over dose, duration, and response are asked to 
determine treatment response or resistance [31].
The Massachusetts General Hospital Antidepressant Treatment Response 
Questionnaire (ATRQ ) is an auto-evaluating scale that defines an appropriate 
antidepressant treatment as optimal dosage during 6 weeks. This questionnaire 
provides operational criteria for adequate dosing of each antidepressant and has 
been used on multiple multicentric studies in TRD. In one study, it was found that 
MGH and ATRQ agree with the independent evaluations of clinical researchers on 
remote interviews [36].
2.3.2 Treatment resistant depression stratification systems
Systems may help predict the ulterior course of depression on the long-term and 
its response to treatment [1]. It is important to point out that all systems based on 
treatment administration have limitations; they were designed when therapeutic 
options available at the time were more limited, and despite their clinical useful-
ness, they have not been properly validated.
Four stratification systems stand out in literature: the Staging Method of Thase 
and Rush [4], the European Staging Method [5, 37], the Massachusetts General 
Hospital Staging model (MGH-s) [6], and The Maudsley Staging Model (MSM) [7].
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treatment administration have limitations; they were designed when therapeutic 
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Thase and Rush proposed five levels of resistance, in which patients are cat-
egorized according to the number and antidepressant class they have failed to 
respond, from the most frequently used to the least usual as MAOIs or ECT [4]. Not 
one degree of each therapeutic trial in terms of dose and duration is recorded; it 
assumes that the non-response to two antidepressant agents of different classes is 
more difficult to treat than the non-response to agents of the same group and that 
the change to an antidepressant of the same group is less effective. The later may 
be true for tricyclic antidepressants, but it is not so at switching between different 
serotonin reuptake inhibitors (SSRIs) [17]. This classification considers that the 
most effective antidepressants on order would be MAOIs, tricyclic antidepressants, 
and SSRIs, which has not been validated on different meta-analyses in antidepres-
sant trials [17, 20]. It also faces the disadvantage of not including other treatments, 
such as drug combinations and psychotherapy, and does not provide prognostic 
information [38]. The Thase and Rush scale is easy to implement and provides an 
accessible strategy for clinicians to treat TRD patients. However, it has been widely 
criticized recently, since its predictive value over the course of treatment has not 
been systematically evaluated [8, 33, 34].
A European Staging Method (ESM) proposes the classification between 
non-responders, patients with TRD, and chronic resistant depression (CRD). 
Non-responders are defined as patients who fail to respond to a method of treat-
ment. Patients are considered TRD if they show poor response to two treatment 
options with different classes of antidepressants at a proper dose over the span of 
6–8 weeks. CRD is defined as a resistant or refractory episode that lasts for more 
than a year despite appropriate therapeutic interventions. This scale has the advan-
tage of including the duration of the depressive episodes and does not suggest a 
hierarchy of antidepressants. Non-response is clearly defined as a reduction inferior 
to 50% on the score of the HAMD [39] or the Montgomery Asberg Depression 
Rating Scale (MADRS) [40] and the TRD stages correspond to the number of failed 
therapeutic trials. It is assumed that patients with failure to respond to two agents 
of different classes would be more resistant than those who do not respond to two 
drugs of the same group and indirectly implies that switching to a drug from the 
same class is less effective [6]. It should be noted that, in this classification, the dif-
ferences between TRD and CRD are arbitrary [8]. ESM does not establish that two 
or more attempts with failed antidepressants imply a higher level of TRD, in con-
trast with the publications that associate the number of changes with poor response 
to treatment [17, 18]. Furthermore, CRD does not consider non-pharmacological 
measures such as ECT or psychotherapy. To date, there are no studies that prove the 
predictive utility or reliability of the scale.
The Massachusetts General Hospital Staging model (MGH-s) was published 
for the first time by Fava [6] based on the scale by Thase and Rush. The MGH-s 
considers dosage optimization and separately prolonging the duration of treatment, 
as well as an operational criterion for minimal dose and duration of treatment. It 
includes measures for titration and combinations and does not rank antidepressant 
classes [41] or an implied preference between them or a change to the same group of 
drugs. The MGH-s considers the number of failed treatments and the intensity and 
optimization of each attempt and generates a continuous variable that reflects the 
degree of resistance to antidepressants. MGH-s generates a continuous score that 
reflects the level of resistance. However, this score is randomly given [8]. Dosage 
optimization and duration are considered equal to increase or combination, which 
does not seem to be backed up on literature [42–44]. Finally, the higher score given 
to ECT is not sufficiently explained [7, 45].
A study published a comparison between the MGH-s and the Thase and Rush 




results showed that both models have a high correlation, but the multivariable analy-
sis demonstrated that the MGH-s had a better prediction for non-remission [45].
Fedaku et al. [7] published The Maudsley Staging Model (MSM) method of 
stratification, in which the TDR score varies from 3 to 15. TRD stages are shown 
in three categories: mild (scores 3–6), moderate (scores 7–10), and severe (scores 
11–15). It incorporates the duration and severity of the depressive episode. MSM 
considers class switching between different antidepressant groups, and between 
the same group has the same score. The scale is easy to use and may be employed 
as a tridimensional model regarding duration, severity, and treatment. It has been 
criticized, however, that disease duration is arbitrary and does not include the 
number of titrating attempts. Empiric value and inter-rate reliability was proven 
with prospective data obtained from the notes of 88 patients on a TRD specialized 
unit and follow-up of 62 patients in this group for a medium of 29.5 months [7].
2.4 Resistant depression treatment general principles
Qualitative and quantitative assessment of depressive symptoms with evaluation 
scales on each visit, assessment tool employment, and watching over adverse effects 
should be a routine practice in the approach to the patient with major depressive 
disorder, and even more so with the TRD patient. Furthermore, it is recommended 
to evaluate psychosocial performance, quality of life, treatment compliance and tol-
erance, and provide 24-h assistance [46]. It is important to encourage patients not 
to abandon treatment or medical attention despite of not perceiving any results. A 
good relationship between the clinician and the patient is also important to guaran-
tee treatment compliance [15]. Finally, the role of psycho-education for the patients 
and their relatives should not be forgotten, as this includes sign and symptom 
identification, prognosis, suicide risk assessment, treatment options, sleep hygiene, 
impulse control, and sleep restriction among others. Behind restriction the initial 
management of depressive patients is usually done by primary care physicians or 
internists, but they should be referred to a mental health specialist if there is not an 
appropriate response to two or more treatments, as well when suicidal or homicidal 
ideation, psychotic or catatonic behavior are detected.
2.4.1 Treatment strategies
For patients with major depressive disorder who do not respond to initial 
treatment with an antidepressant, there are diverse management strategies  
[5, 14, 30, 47–50] which have been classified and arranged in three groups as 
follows: (1) optimization; (2) treatment switching (to a different antidepressant, 
psychotherapy, or ECT); (3) augmentation or adding other treatment to the 
one already in use, such as a different drug, psychotherapy, or ECT (Table 1). 
Regardless of the strategy, it is recommended always to use one strategy at a time 
to assess which is the most effective. We will review each one of them.
2.4.1.1 Optimization
Optimization consists of improving the current treatment, while supervising 
good tolerance. It should be noted that, in some studies with patients diagnosed 
as resistant and sent to specialized clinics, it has been reported that an important 
number of them did not receive an appropriate dose of the medication or had been 
taking it behind for a brief period of time [51]. This would represent a case of 
pseudo-resistance. Several studies show that it is important to treat a major depres-
sive episode for 6–12 weeks before concluding non-remittance [6, 26, 52]. A study in 
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results showed that both models have a high correlation, but the multivariable analy-
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tee treatment compliance [15]. Finally, the role of psycho-education for the patients 
and their relatives should not be forgotten, as this includes sign and symptom 
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impulse control, and sleep restriction among others. Behind restriction the initial 
management of depressive patients is usually done by primary care physicians or 
internists, but they should be referred to a mental health specialist if there is not an 
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2.4.1 Treatment strategies
For patients with major depressive disorder who do not respond to initial 
treatment with an antidepressant, there are diverse management strategies  
[5, 14, 30, 47–50] which have been classified and arranged in three groups as 
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one already in use, such as a different drug, psychotherapy, or ECT (Table 1). 
Regardless of the strategy, it is recommended always to use one strategy at a time 
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2.4.1.1 Optimization
Optimization consists of improving the current treatment, while supervising 
good tolerance. It should be noted that, in some studies with patients diagnosed 
as resistant and sent to specialized clinics, it has been reported that an important 
number of them did not receive an appropriate dose of the medication or had been 
taking it behind for a brief period of time [51]. This would represent a case of 
pseudo-resistance. Several studies show that it is important to treat a major depres-
sive episode for 6–12 weeks before concluding non-remittance [6, 26, 52]. A study in 
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1627 patients, where 67% of them received less than 4 weeks of treatment and did 
not show response to an antidepressant [53], did not find any difference between 
continuing the current treatment or changing to another antidepressant. This sup-
ports the importance of keeping the patients on an antidepressant treatment for an 
appropriate amount of time before changing it. On the other hand, multiple studies 
show that if patients have less than 25% reduction of symptoms after 4 weeks treat-
ment, it could be indicated to switch to a different treatment strategy [54].
2.4.1.2 Treatment switching
Treatment switching is the act of suspending the current treatment and replacing 
it with a different pharmacologic or non-pharmacologic anti-depressive strategy. 
This includes using a different antidepressant, switching to psychotherapy, or ECT.
2.4.1.3 Changing antidepressants
It has been suggested that, in order to switch antidepressant medications, the 
current medication should be gradually discontinued while the new one is slowly 
introduced throughout 1–2 weeks and the dosage of the new antidepressant agent 
should be given at a corresponding amount to the one being discontinued. The clini-
cian should be aware of increases of adverse effects and, in relation to SSRIs, the risk 
of serotonin syndrome. Some clinicians prefer to switch from an SSRI to another 
instantly, except when the patient has received fluoxetine, where the waiting time 
should be no less than 4 weeks before using another SSRI due to its long half-life.
For patients resistant to SSRIs, it has been suggested to switch to a selective nor-
adrenaline and serotonin reuptake inhibitor (SNRI), atypical antidepressants, such as 
bupropion or mirtazapine, tricyclic antidepressants, or MAOIs. There are, however, 
few studies that compare switching to each one of these groups of drugs. In one 
meta-analysis that included four randomized studies with 1496 patients resistant to 
an SSRI, remission was evident in 24% of the patients who received another SSRI, and 
in 28% who were introduced to a different class of antidepressant such as bupropion, 
mirtazapine, or venlafaxine [55]. Regarding patients resistant to SSRI, many studies, 
including some meta-analyses, support changing to venlafaxine [17, 55]. A meta-
analysis with 3375 patients with depression resistant to an SSRI showed that changing 
to another SSRI led to remission on 45% of the subjects, but 54% remitted when 
changing to venlafaxine [17]. Concerning atypical antidepressants, the few compara-
tive studies available on TRD patients have not found differences respecting efficacy 
[18, 42]. In a group of patients resistant to paroxetine, a study that compared extended 
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release venlafaxine (225 mg/day) and mirtazapine (45 mg/day) found remissions of 41 
and 36% respectively [56]. In another study, 477 patients resistant to an SSRI treated 
for 14 weeks with bupropion SR (average dose 238 mg/day) or sertraline (average dose 
136 mg/day) remission was achieved on 21 and 18% of the subjects, respectively [57]. 
An 8-week study that compared mirtazapine (45 mg/day) with paroxetine (20 mg/
day) in 100 patients with TRD, remission was achieved in 36 and 47% with similar 
tolerance. Finally, a comparative study with mirtazapine (average dose 30 mg/day) 
and sertraline (average dose 120 mg/day) in 250 TRD patients, remission was similar 
(38 versus 28%, respectively) without statistical difference [58–60]. Nevertheless, 
there were more adverse effects with mirtazapine such as sedation, fatigue, weight 
gain, and xerostomia. In TRD patients, efficacy and tolerability of tricyclic antide-
pressants is comparable to that of atypical antidepressants and SSRIs [61]. Currently, 
tricyclic antidepressants have become the fourth or fifth line of treatment in TRD 
patients due to undesired adverse effects such as anticholinergic effects, cardiotoxic-
ity, and lethal potential with overdose. The STAR*D study reported the fourth or fifth 
line of treatment in major depressive patients due to undesired adverse effects such 
as anticholinergic effects, cardiotoxicity, and lethal potential with overdose. In TRD 
patients, efficacy and tolerability of tricyclic antidepressants is comparable to that of 
atypical antidepressants and SSRIs. In the STAR*D study, an open 14-week trial in 235 
patients compared nortriptyline (average dose 97 mg/day) with mirtazapine (average 
dose 42 mg/day) showing a comparable remission of 20 versus 12% and equal toler-
ance [62]. In a double-blind randomized study, 168 imipramine- or sertraline-resistant 
patients treated for 12 weeks were randomly assigned to the other treatment [63]. 
Remission was comparable (23% versus 32%) with more discontinuation with imip-
ramine switching due to adverse effects (9 versus 0%). MAOIs are rarely used today, 
since they carry lethal potential by interacting with other drugs and food containing 
tyramine [64]. Nevertheless, changing to a MAOI may still be helpful for some TRD 
patients [17, 64]. A randomized trial with 46 imipramine-resistant patients who 
received phenelzine (45–90 mg/day) for 6 weeks and 22 phenelzine-resistant patients 
who were switched to imipramine (150–300 mg/day) reported a higher response on 
patients who received phenelzine rather than imipramine (67 versus 41%) [64]. For 
severely depressed patients with TRD, there is not enough evidence that indicates 
which kind of antidepressant is superior [65]. Tricyclic antidepressants may be pre-
ferred [66]. However, a meta-analysis of 25 randomized trials on 1377 hospitalized 
depressed patients who received tricyclic antidepressants or SSRIs showed that tricyclic 
antidepressant superiority over SSRIs was low with a higher rate of adverse effects [67].
2.4.1.4 Switching to psychotherapy
Changing from a pharmacologic approach to psychotherapy may be rejected by 
many TRD patients [68], but still is a reasonable approach. A 12-week trial with 122 
patients who did not respond to citalopram and were randomized to cognitive behav-
ioral therapy (CBT) or different antidepressants (bupropion, sertraline, or venlafax-
ine) [68] reported similar remission (25 and 28%). Another study with 140 patients 
who did not respond to a trial with nefazodone or CBT and then were switched to the 
other treatment [69] reported a comparable remission of 36 and 27%, respectively.
2.4.1.5 Electroconvulsive therapy
For patients with TRD with severe depression, ECT continues to be the therapy 
of choice [28, 66, 70–72]. The most important indications for ECT are persistence 
of suicidal ideation, suicide attempt, severe weight loss with malnutrition, dehydra-
tion, food or fluids rejection, and malignant catatonia. ECT is also indicated in cases 
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of depression with psychotic symptoms and if there is previous history of response 
to this treatment. ECT has been shown superior to pharmacotherapy as shown by 
multiple meta-analyses and randomized studies [65]. A meta-analysis of 18 studies 
with 1144 patients that compared ECT with pharmacotherapy found that ECT was 
more effective [71]. ECT approach is recommended by many guidelines [66, 70, 
72, 73]. ECT is not exempt of anesthetic risks, adverse effects, logistic problems, 
treatment rejection, and relapse.
2.4.1.6 Augmentation
Augmentation consists of adding other treatment (pharmacologic or non-
pharmacologic) to the current one [74]. A new drug, psychotherapy, or transcranial 
magnetic stimulation (TME) might be added. This approach has been widely used 
and studied; combination therapy with antipsychotics, lithium, or triiiodothyro-
nine (T3) are generally well tolerated [52, 58, 75–79], while combination therapy of 
MAOI with other antidepressants may cause serotonin syndrome or hypertensive 
crisis [80]. Previous response, safety, comorbidities, ease of use, patient’s prefer-
ence, and costs are factors to consider while adding other drugs to the current treat-
ment. TRD patients, who have had additions and do not respond in 6–12 weeks at 
the desired dose or do not tolerate the combination, should be switched to a second 
combination [58]. Some authors suggest discontinuation of the supplementary drug 
and addition of a new one progressively over 1–2 weeks [58].
2.4.1.7 Adding a second antidepressant
Concerning depression with partial response to monotherapy with antidepres-
sants, a second drug is usually added. However, a meta-analysis of eight studies 
with 808 patients that did not respond to monotherapy and that compared anti-
depressant combination with monotherapy, found a similar improvement on both 
groups [81]. The most studied antidepressants are mirtazapine and bupropion.
Mirtazapine use as an augmentation drug on TRD patients is supported by the 
results of open and placebo-controlled studies [81, 82]. On the STAR*D study, 
mirtazapine was added to patients resistant to venlafaxine and was compared with 
switching to tranylcypromine (a MAOI). Both approaches had no different effects 
[83]. However, addition of mirtazapine to resistant patients requires additional 
studies to establish its efficacy.
Bupropion, a noradrenergic/dopaminergic reuptake inhibitor, was studied in 
TRD patients [84]. Bupropion has a good tolerability and low side effect profile, 
including few sexual side effects.
Buspirone, a serotonin (5-HT1A) receptor partial agonist, was studied in ran-
domized, double-blind, placebo-controlled trials combined with an SSRI in patients 
with TRD [85]. Buspirone, at a dosage of 41 mg/day, was compared on the STAR*D 
study with Bupropion SR at 267 mg/day, with similar effectiveness [44]. As with 
mirtazapine, bupropion addition is a popular practice as an enhancing maneuver, 
but additional studies are needed to justify its use on TRD patients.
2.4.1.8 Second-generation antipsychotics
For second-generation antipsychotics in patients with TRD, the following order 
was suggested based on benefit and a lower rate of adverse effects: aripiprazole, 
quetiapine, risperidone, and less frequently ziprasidone or olanzapine [58, 77, 86, 87]. 
Also, the use of brexpiprazole has been suggested if aripiprazole generates akathi-




olanzapine, quetiapine, or risperidone with placebo on 3480 patients with 
non-psychotic depression who failed to at least one attempt with antidepressant 
monotherapy [90] showed improvement in 31% of the patients who received the 
additional drug (31%) versus placebo (17%). Discontinue due to adverse effects was 
higher with antipsychotics (9 versus 2%), 4% for aripiprazole, 12% for quetiapine, 
and 7% for risperidone [90]. In an open, randomized 12-week trial with 1522 
patients who stayed severely depressed after treatment with an antidepressant [75], 
the subjects received three types of treatments: aripiprazole increase (target dose 
5–15 mg/day), bupropion increase (target dose 300–400 mg/day), or switching 
to bupropion. Response (reduction equal or higher than 50% of depression) was 
greater with aripiprazole (74%) than increasing bupropion (66%) or switching 
to bupropion (62%). There were more adverse effects with aripiprazole, such as 
akathisia, somnolence, weight gain, and laboratory abnormalities, but patients 
experienced more anxiety with bupropion. A meta-analysis of 11 randomized trials 
on TRD patients (n > 3000) found that effectiveness of the augmentation of atypi-
cal antipsychotics might rise with the increase of the resistance [90]. For example, 
the augmentation may carry more benefit for patients that do not respond to three 
or four failed attempts compared with those who do not respond to one.
2.4.1.9 Lithium
Augmentation of treatment with lithium was reported for the first time by De 
Montigny by combining it with tricyclic antidepressants [91]. Thereafter, multiple 
studies have demonstrated its efficacy. A meta-analysis of 10 placebo, controlled stud-
ies showed that the addition of lithium at a dose to 600–900 mg/day (plasma levels 
higher than 0.4 mEq/L) was superior to placebo [78, 92]. A meta-analysis of nine 
trials with 237 patients comparing lithium versus placebo found a higher response 
with lithium [84]. Lithium was effective in the augmentation with first- and second-
generation antidepressants attached to a possible benefit in reducing suicide risk. A 
meta-analysis of nine studies with 234 patients, where double-blind trials with lithium 
and placebo on TRD patients were included, showed a broad effectiveness with this 
approach [93]. The authors concluded that it should be given for no less than 7 days 
at dose of 600–800 mg/day [93]. An analysis of the literature reviewing 12 random-
ized studies on lithium augmentation of SSRIs or atypical antipsychotic drug therapy 
found no statistical difference that favors the use of one approach or the other [94].
2.4.1.10 Thyroid hormone
Thyroid hormone, in particular T3, has been used as an augmenting agent since 
the 1960s [95]. The usual dose of T3 in the form of liothyronine is 25–50 pg and 
with thyroxine (T4) is 150 pg. An initial meta-analysis with T3 showed effectiveness 
against placebo [79]. Subsequent studies, however, have shown limited evidence 
of its effectiveness. A meta-analysis with four randomized studies with 95 patients 
who did not respond to tricyclic antidepressants compared augmentation with T3 
versus placebo or T4 showed response in 53% patients who received T3 but had 
not statistical difference with placebo [79]. However, T3 augmentation is not very 
popular in the UK nor in the USA [96].
2.4.1.11 Repetitive transcranial magnetic stimulation
Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive technique 
in which a sequence of high-intensity magnetic pulses is used to stimulate cortical 
neurons to treat neuropsychiatric disorders including major depressive disorder 
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trials with 237 patients comparing lithium versus placebo found a higher response 
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generation antidepressants attached to a possible benefit in reducing suicide risk. A 
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and placebo on TRD patients were included, showed a broad effectiveness with this 
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ized studies on lithium augmentation of SSRIs or atypical antipsychotic drug therapy 
found no statistical difference that favors the use of one approach or the other [94].
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the 1960s [95]. The usual dose of T3 in the form of liothyronine is 25–50 pg and 
with thyroxine (T4) is 150 pg. An initial meta-analysis with T3 showed effectiveness 
against placebo [79]. Subsequent studies, however, have shown limited evidence 
of its effectiveness. A meta-analysis with four randomized studies with 95 patients 
who did not respond to tricyclic antidepressants compared augmentation with T3 
versus placebo or T4 showed response in 53% patients who received T3 but had 
not statistical difference with placebo [79]. However, T3 augmentation is not very 
popular in the UK nor in the USA [96].
2.4.1.11 Repetitive transcranial magnetic stimulation
Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive technique 
in which a sequence of high-intensity magnetic pulses is used to stimulate cortical 
neurons to treat neuropsychiatric disorders including major depressive disorder 
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[97]. This technique may be ambulatory, can be added to the current antidepressant 
treatment, and has good tolerability. Initial systematic reviews on mixed popula-
tions of depressed patients that included non-resistant patients supported their use 
on TRD patients [98–103]. A meta-analysis of 24 trials that included 1092 patients 
who underwent rTMS and sham conditions showed rTMS was superior in clinical 
improvement of patients with TRD. The response and remissions were 25 and 17% 
and 9 and 6% for the rTMS and sham conditions, respectively [104]. Short duration 
rTMS (1–4 weeks) has an evident antidepressant effect on TRD patients and is well 
tolerated. Nevertheless, remission rates and responses with rTMS are low and it is 
unknown if there is a sustained effect. Not known is whether effects of TMS are 
sustained over time and its speed of onset [104].
2.4.1.12 Psychotherapy
Addition of CBT usually helps TRD patients, as demonstrated by multiple ran-
domized studies [105–107]. In a randomized 1-year study with CBT (12–18 sessions), 
it was observed that remission occurred more on CBT group of patients (28%) than 
in patients who did not receive it (15%). In another study, depressive symptoms were 
minor on a self-report 40 months after patients received CBT [108]. A 12-week study 
compared citalopram plus 16-session CBT with citalopram plus additional phar-
macological approaches such as bupropion or buspirone in 182 ambulatory patients 
resistant to citalopram [109]. The number of patients who achieved remission was 
similar (23 and 33%). A 12-week study that compared nefazodone treatment with 
16- to 20-session CBT versus nefazodone alone on 446 ambulatory patients with 
chronic depression (medium of 8 years) showed remission in more patients under-
going the combination (48 versus 29%) [110]. In hospitalized patients with severe 
depression, combination therapy is a common practice and its effectiveness is clear. 
A 12-week study that compares CBT and pharmacotherapy with pharmacotherapy 
alone in 20 hospitalized patients with chronic depression found a similar improve-
ment [111]. An observational 12-week study with CBT added to pharmacotherapy 
in 24 hospitalized patients with chronic depression [112] found a 46% reduction in 
depressive symptoms. In TRD patients, other types of psychotherapy such as group, 
family, or interpersonal therapy have not been well studied.
2.4.1.13 Other addition maneuvers
Several addition maneuvers have been employed in TRD patients, such as 
lamotrigine combination, stimulants like methylphenidate, modafinil, and pindolol 
among others. A meta-analysis which included 10 studies with 289 patients undergo-
ing lamotrigine treatment concluded that this drug had little effect on non-bipolar 
TRD patients [113]. Controlled studies evaluating placebo versus methylphenidate 
have been negative despite its regular use [114]. Modafinil did not show a sustained 
effect in two controlled studies. However, a subsequent retrospective analysis 
suggests that modafinil may help TRD patients with fatigue and somnolence [115]. 
Pindolol, a non-selective beta-adrenergic antagonistic with effect in the 5-HT1A 
auto-receptor has shown negative results against placebo on TRD patients [116]. 
N-methyl-D-aspartate (NMDA) receptor acting drugs like memantine, ketamine, 
and riluzole have been studied. Controlled studies with memantine, an NMDA-
receptor antagonist, have been negative [117]. Ketamine, an NMDA-receptor 
antagonist anesthetic, has shown positive antidepressant results in a controlled 
study against placebo in patients with TRD [118]. Riluzole, a putative glutamate 
release inhibitor used in the treatment of amyotrophic lateral sclerosis, did not show 




2.4.2 Studies comparing switching versus augmentation maneuvers
Multiple guidelines suggest how to use augmentation or switching maneuvers 
(The American Psychiatric Association, United Kingdom National Institute 
of Health and Clinical Excellence guidelines among others) [28, 66, 120, 121]. 
However, few randomized studies comparing the effectiveness of these maneuvers 
on TRD patients have been performed and most of them do not differ between 
those patients with little or no benefit from those who improve partially.
Various studies show that augmentation or switching maneuvers are equally 
efficient. Thus, multiple evaluations reviewing placebo-controlled randomized 
studies regarding augmentation and switching approaches show similar results 
[76]. The medium rate of remission with augmentation was 27% and switching 
was 22%, with response rates (reduction of 50% or more of the symptoms) of 38 
and 40%, respectively [122]. A prospective study with citalopram on two groups of 
269 patients who preferred augmentation with bupropion or buspirone to switch-
ing citalopram to bupropion, sertraline, or venlafaxine had a similar remission. A 
randomized study with 375 TRD patients, where several treatments were assigned, 
including five augmentations and two switching options [123, 124] showed similar 
results with 37 and 41% for each strategy. On the other hand, in a group with 1522 
patients (85% men), almost 50% of them undergoing post-traumatic disorder, 
and who continued severely depressed after the first course of treatment with an 
antidepressant, almost all of them on psychotherapy, the augmentation approach 
with aripiprazole (5–15 mg/day) or bupropion (300–400 mg/day) was slightly 
superior to switching antidepressants to bupropion as monotherapy [75]. Remission 
was achieved in 29% of the patients with aripiprazole augmentation, 27% with 
bupropion augmentation, and 22% with switching to bupropion. Surveillance over 
24 months of the remitted patients (n = 396) showed that approximately 25% of the 
patients in each group relapsed. There were more adverse effects in the aripiprazole 
group [75]. Other studies show that augmentation approach with aripiprazole may 
be more effective in women than in men [125].
With patients not tolerating the antidepressant dose, it is preferable to switch 
antidepressants. While there is evidence that suggests that augmentation is somehow 
superior to switching antidepressants, the decision should be discussed with the 
patient. Clinical criteria would be that patients who have had partial benefit from 
the initial antidepressant and have few adverse effects may prefer an augmentation 
approach and those with less improvement and more adverse effects might prefer 
switching medication. However, in patients resistant to a second treatment, there is no 
evidence that shows how many approaches should be done before considering change 
of treatment. Authors suggest 1–3 trials before switching [58, 74]. Changing medica-
tions has the advantage of achieving a better compliance to treatment than when more 
than one medication is used [126] adding a lower risk of adverse effects, pharmaco-
logic interactions, and costs. A study evaluated 48 trials that included 6654 patients. 
A comparison was made between randomized studies, which compared 11 agents 
used on augmentation approaches: atypical antipsychotics (aripiprazole, olanzapine, 
quetiapine, and risperidone), antidepressants (bupropion, buspirone), lithium, thy-
roid hormone, methylphenidate, pindolol, and lamotrigine [87]. The studies analyzed 
were compared between them or placebo in patients with TRD and the proportion 
of patients who responded to treatment was defined as primary effectiveness. The 
analysis showed that primary effectiveness was higher with quetiapine, aripiprazole, 
thyroid hormone, and lithium in relation to placebo, but even higher for the former 
two in the sensibility analysis. There were no differences regarding discontinuation 
rate and adverse effects (acceptability) for these treatments [87]. Quetiapine, olan-
zapine, aripiprazole, and lithium were less well tolerated than placebo [87].
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A randomized 8-week study on 140 TRD patients with paroxetine plus risperi-
done, paroxetine plus trazodone, and paroxetine plus thyroid hormone showed 
similar remission rates of 27, 43, and 38%, respectively [123]. A 6-week randomized 
open study that compared adding quetiapine (target dose 300 mg/day) with adding 
lithium (target plasma concentration from 0.6 to 1.2 mmol/L) in 450 resistant 
patients got a similar remission rate of 32 and 27%, respectively [127].
A meta-analysis with 48 randomized trials (n > 6000 depressed patients) in 
which efficiency of augmentation agents was evaluated using results from compari-
sons between drugs (on head to head trials), as well as indirect comparisons of the 
drugs through their relative effects with a common comparator (typically a pla-
cebo) [123]. The response (reduction equal or higher than 50%) or remission was 
more frequent when aripiprazole, lithium, olanzapine, quetiapine, risperidone, or 
thyroid hormone (T3 or T4) was added, compared to placebo; results from each one 
were comparable. Discontinuation due to adverse effects was higher with aripipra-
zole, lithium, olanzapine, and quetiapine than with placebo.
2.4.3 Promising new treatments
2.4.3.1 Acetylcholine receptor acting drugs
Medications that act on the cholinergic system seem promising in the treatment 
of TRD patients. Controlled studies versus placebo with intravenous scopolamine 
(a muscarinic antagonist) in TRD patients showed promising results [128]. 
Mecamylamine, a nAChR antagonist added to citalopram, was also superior to 
placebo [129]. Other drugs like mecamylamine, S-mecamylamine, and varenicline 
are currently in a preliminary stage of study in depressive patients [129, 130].
2.4.3.2 N-methyl-D-aspartate (NMDA) acting drugs
Ketamine, an NMDA-receptor antagonist, has shown antidepressant effects in 
TRD patients in a controlled study versus placebo [118]. However, ketamine, a dis-
sociative anesthetic administration which complicates TRD patient treatment due 
to its route of administration (intravenous), requires hospitalization and consulta-
tion with an anesthesiologist. The rapid effects of ketamine usually disappear in 
4–6 days. Also, it is possible that patients who improve on ketamine require a long-
term course of maintenance. Ketamine has been given intranasal, or by sublingual 
delivery. Lapidus et al. [131] compared intranasal administration of ketamine 50 mg 
and placebo in 20 TRD patients. Patients improved at 24 h, but not at 72 h after 
administration. Recent studies are currently researching intranasal administration 
of esketamine, the S-enantiomer of racemic ketamine on TRD patients. Initial 
results are very promising [132]. If accepted, esketamine would enter the list of 
enhancement approaches for TRD patients.
Deep brain stimulation, vagus nerve stimulation, and neurosurgical lesions have 
also been evaluated in different studies as therapeutic options in highly resistant 
TRD patients [133].
2.5 Neurobiological aspects of resistant depression
Most antidepressants act by modulating serotonin, noradrenaline, and dopa-
mine neurotransmission, but other neurotransmission routes seem to be involved 
such as cholinergic, glutamatergic, neuropeptides, and neuromodulators among 
others. The complex neurotransmission systems are prone to failure in the short- 




treatments seem to exert action by different mechanisms modulating different 
cerebral regions [134]. Genetic variants may explain up to 42% of antidepressant 
response [135]. Genetic polymorphisms for cytochrome P-450 (CYP) enzymes 
may lead to a reduction on enzyme activity of the CYP2D6 or CYP3A4 variants, 
leading to intolerance to antidepressants on high plasmatic levels [136, 137]. Some 
patients are rapid metabolizers, resulting in low plasmatic levels at standard doses 
of antidepressants, leading to resistance. Evaluation of these genetic variants is 
accessible with pharmacogenetic studies of antidepressants. Other resistance 
genetic variants may be related to p-glycoprotein (p-gp), also known as the ABCB1 
drug multiresistance gene [138]. Besides this, other polymorphic variants have 
been associated with response to antidepressants. In the case of serotonin 2A gene 
(HTR2A), both coding and noncoding polimorphisms have been associated to low 
SSRIs response [139–141]. Furthermore, single nucleotid polymorphisms (SNPs) 
of the genes for brain-derived neurotrophic factor (BDNF) [142, 143], the norepi-
nephrine transporter [144], tryptophan hydroxylase 2 [145, 146], corticotrophin 
releasing hormone receptor 1 [147], the glucocorticoid receptor [148, 149], and the 
common promoter polymorphism of the serotonin transporter gene [150–155] have 
been associated with low SSRI response.
It has been published that the activation of the immune system and neuroin-
flammation represent a primary event in the pathophysiology of TRD [156–158] 
and that the effect of NSAID may increase the effect of antidepressants [159].
Finally, the catecholaminergic hypothesis of depression [160, 161], which asso-
ciates depression with low levels of neurotransmitters, was accepted to explain 
not only the neurobiochemistry of depression, but also the effect of antidepres-
sant drugs. This hypothesis postulates that, in depression, the function of the 
dopamine, noradrenaline, and indolamine serotonin monoamines is decreased. In 
support of this, different studies have shown changes in plasma, urine, and cere-
brospinal fluid concentrations of these neurotransmitters and their metabolites, 
changes in the density of neuroreceptors in platelets and neurons, flattened curves 
in neuroendocrine challenges and also early relapses with the blockade of restric-
tion enzymes for neurotransmitter synthesis in patients who had achieved depres-
sion remission with antidepressant treatment [162]. The existence of subtypes 
of depression, where noradrenergic, serotoninergic, or dopaminergic negative 
balance is predominant, has been also postulated. Patients with these subtypes 
of depression hypothetically would respond better to antidepressant drugs with 
noradrenergic, serotoninergic and dopaminergic effects. Unfortunately, clinical 
studies on the effect of antidepressants with different mechanisms of action show 
contradicting results, and today there are not clear clinical or biological parame-
ters to predict the results of different antidepressant treatments [163]. It should be 
noted that any theory about the cause of TRD would be simplistic including that 
the deficit of a single neurotransmitter, genetic, or immune system and neuroin-
flammation responses would be present in most TRD patients. However, knowing 
if there are groups of patients that may respond better to drugs with different 
mechanisms of action continues to be important for the treatment of patients with 
TRD [164].
It has been suggested that, in the selection of an antidepressant drug, the clini-
cian must observe the overall response of the patient with major depression [165]. 
Also, in the selection of an antidepressant drug, the clinician must observe the pos-
sible relationship between the drug’s biochemical effect and its effects on specific 
symptoms but also on adverse events. This became more relevant when a drug or 
group of drugs have failed to improve the patient and a new one has to be supplied, 
when adverse events force treatment change or when augmentation or change of 
antidepressant treatment is considered.
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3. Conclusions
Once resistance to treatment with two drugs with different action mecha-
nisms has been established, the next best therapeutic decision is terra ignota 
because there is not enough scientific information available to validate which 
steps are to follow: whether change treatment, adding an antidepressant, “buster 
therapies” like addition of lithium, thyroid hormone or stimulants, add atypical 
antipsychotics, rTMS or employment of newly treatments such as ketamine, or 
ECT. In the evaluation stages for the treatment of a patient with TRD it is impor-
tant to make an evaluation and reassessment of the case. This includes confirm-
ing the diagnosis of major depressive disorder, making the differential diagnoses 
of bipolar depression or other forms of resistant depression such as secondary 
to other medical issues, drugs, etc. Medical and psychiatric comorbidities, as 
well as depression severity should be assessed. Also, a detailed clinical history on 
antidepressant use should be performed. The application of diagnostic tools or 
evaluation scales is relevant.
Despite of its importance and frequency, there is no consensus over what TRD 
is. Advances have been made over assessment tools to evaluate resistance to treat-
ment. However, there is no consensus over which is the best stratification system 
for TRD. There is a lack of research that validates which treatment approaches 
may be more effective and which ones should be used in the different stages in the 
management of a resistant patient. Unfortunately, advances over neurobiology of 
depression cannot be transferred yet to a clinical level to help the physician choose 
the best treatment for a patient with major depression and even less so for a TRD 
patient [163, 164]. In patients who have an inadequate response to the first line of 
treatment, the clinician has many options to change the treatment, but if the second 
approach fails, other approaches seem to be equally effective in according to what 
is published on the literature and there are no clear guidelines that support one or 
the other. This outlook is discouraging for patients and physicians who are on trial 
and error until they find something that helps the patient. Future research on TRD 
patients should be centered on neurobiological factors involved in the development 
of the resistance including pharmacogenetics. Without the development of tech-
niques that help us predict which factors are related to this phenomenon, treatment 
of TRD patients will continue to be insufficient.
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the Developing Offspring
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Abstract
Maternal vulnerability to adversity has long-term impact on the developing 
child. About 20% of the pregnant women suffer from affective disorders. Fetal 
exposure to maternal adversity may lead to detrimental consequences later in 
life. Maternal affective disorders are increasingly treated with antidepressants, 
especially selective serotonin reuptake inhibitors (SSRIs). However, the long-term 
consequences for the offspring after exposure to this medication are unclear. The 
interplay between maternal adversity and SSRI treatment has been under inves-
tigation and here we discuss how maternal adversity and SSRIs are able to shape 
offspring development. Specifically, we will discuss animal models addressing 
behavioral outcomes to understand how the prenatal environment influences the 
health of the developing child across the life span.
Keywords: maternal vulnerability, maternal depression, selective serotonin reuptake 
inhibitors, antidepressants, pregnancy, neurodevelopment
1. Introduction
Although pregnancy is often portrayed as a time of great joy, that is not the reality 
for all women. Depressive symptoms during pregnancy are not uncommon; in fact, 
20% of women experience some depressive symptoms during any time of their 
pregnancy [1]. The number of women who suffer from major depression during 
pregnancy is estimated to be 4–8% [2, 3]. According to the DSM-5, this disorder is 
characterized by a depressed mood or loss of interest or pleasure in daily activities for 
more than 2 weeks. Depression is accompanied by impaired social, occupational, and 
educational functioning. Untreated antenatal depression, that is to say a depressive 
episode during pregnancy, may have a tremendous effect on the developing child [4].
Maternal vulnerabilities during pregnancy, such as depression, anxiety, or high 
stress levels due to other reasons, are associated with increased and continued 
activation of the hypothalamic-pituitary-adrenal (HPA) axis. The continued activa-
tion of the HPA axis in depressed patients causes an elevated stress response and 
increased cortisol levels [5]. About 40% of the cortisol passes through the placenta 
[6]. Consequently, increased cortisol levels are found in the urine and saliva of the 
infants of depressed mothers [7].
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Fetal exposure to increased maternal stress levels impacts the developing child. 
For example, high levels of maternal cortisol are associated with reduced neurologi-
cal development [8] and altered cortisol responses of the unborn child to a stressor 
[9]. Furthermore, maternal vulnerabilities such as anxiety, depression, and elevated 
stress levels are associated with the increased fearful temperament and negative 
behavioral reactivity to novelty in infants [9, 10], and delayed cognitive and neuro-
motor development [11, 12] that persists into adolescence [13]. In addition, antenatal 
depression has also been linked with disturbed sleep patterns in infants [14] and in 18 
and 30 months old children [15]. Furthermore, antenatal depression has been linked 
to reduced fetal growth [16, 17] and altered cardiovascular responses to stress [18].
Several studies have looked into the effects of maternal vulnerability on the 
behavioral development of the child. For example, maternal anxiety, but not ante-
natal depression is linked to a difficult child temperament at the age of 4–6 months 
[19], an increase in behavioral and emotional problems at the age of 4 [20] and 
more internalizing behavior at the age of 8 [21]. Moreover, antenatal depression is 
associated with delayed development in 18-month-olds [22], increased external-
izing behaviors and a slight decrease in IQ in 8-year-old children [21], and violent 
behavior during adolescence [23]. On the long-term prenatal exposure to maternal 
depression is associated with a higher chance of developing depression during ado-
lescence [24, 25] and adulthood [26], or risk of developing other psychopathologies 
[27]. Maternal anxiety as well as maternal depression during pregnancy is correlated 
with child attention problems at the age of 3 and 4 [28]. Moreover, an increase in 
reporting symptoms of antenatal depression and anxiety positively correlated with 
an increase in internalizing behaviors in 4-year-olds [29]. So anxiety and depression 
appear to have similar but, at the same time, different effects on offspring develop-
ment; however, it is difficult to discern between maternal anxiety and depression, 
due to common comorbidity between these mental health conditions [30].
Overall, maternal vulnerability, such as depression and anxiety, during preg-
nancy can negatively influence the unborn child on both physiological and behav-
ioral levels. However, it remains difficult to discern the direct effects of antenatal 
depression (an aversive postnatal environment due to a depressed mother), and 
genetic predisposition to vulnerability on fetal and infant development. In addition, 
an increasing percentage of women suffering from depression and/or anxiety are 
treated with antidepressants, which on itself might have tremendous effects on the 
developing child.
2. Maternal SSRI treatment and offspring development
Pharmacological treatment of antenatal depression and/or anxiety is sometimes 
unavoidable. The treatment with antidepressants may relieve the symptoms of 
the depression of the mother and could help in reducing the impact on the unborn 
child. Nowadays, a considerable number of women are treated with antidepressants 
during pregnancy. In Europe, this concerns 2–3% of the pregnant women [16, 31], 
while in the U.S., the occurrence is as high as up to 13% [32, 33]. The most pre-
scribed antidepressants are selective serotonin reuptake inhibitors (SSRIs), because 
of their good efficacy, few side effects, and therapeutic safety [34]. These drugs 
work by blocking the serotonin transporter and hereby preventing the reabsorption 
of the neurotransmitter serotonin into the presynaptic nerve cell. Subsequently, 
extracellular serotonin levels in the synaptic cleft are increased and more serotonin 
is available to bind the postsynaptic receptors. Although, SSRIs are considered safe 
for antenatal use [35], it has been reported that the use of SSRIs during pregnancy 
may negatively influence the development of the unborn child. SSRIs can cross the 
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placenta and are found in the amniotic fluid [36, 37], affecting therefore not only 
the mother but also the developing child. This is of extra concern as serotonin plays 
a key role in embryonal development. During the development of the fetal brain, 
serotonin acts as a neurotrophic factor, regulating cell division, differentiation, 
migration, growth cone elongation, dendritic pruning, myelination, and synapto-
genesis [38]. In fact, serotonin receptors and serotonergic metabolic enzymes are 
expressed before serotonin-producing neurons are present in the brain [39]. Thus, 
changes in the serotonin levels during neurodevelopment, for instance, by the 
administration of SSRIs during pregnancy, potentially affect a number of processes 
in the offspring.
Indeed, literature shows a number of side effects in the offspring due to prenatal 
SSRI exposure. First of all, SSRI exposure during pregnancy has been associated 
with attenuated basal cortisol levels in neonates [40, 41], and differential cortisol 
levels in 3-month-old infants in response to a stressor [42]. Also, the neonatal heart 
rate response to an acute noxious event is attenuated [43]. Furthermore, several 
behavioral changes have been reported, such as increased internalizing behaviors, 
such as depression, anxiety, and social withdrawal during childhood [44, 45], 
increased externalizing behaviors in 4-year-old children [46], and disrupted sleep 
patterns in newborn [47]. In addition, SSRIs reduce utero-placental blood flow, a 
mechanism thought to be involved with hypertension in preeclampsia and gesta-
tional diabetes [48, 49].
Recently, there has been much interest in the link between antenatal SSRI 
treatment and the development of autism spectrum disorders (ASDs) in the 
child. ASD is a neurodevelopmental condition characterized by difficulties in 
social communication and unusually restricted, repetitive behavior and inter-
ests. The available literature shows an association between the prenatal use of 
SSRIs and the increased risk of ASDs in the child [50–54]. It is theorized that 
this is facilitated by an increase in serotonergic activity during brain develop-
ment [55]. Several studies found abnormal placental histology to be associated 
with autism diagnosis [56, 57]. Moreover, autistic patients have elevated blood 
platelet serotonin levels [58, 59]. Taken together, these results imply the seroto-
nergic influences on maternal-fetal interaction, although the exact mechanisms 
remain elusive.
A possible route for passing adverse intra-uterine effects to the fetus is via 
epigenetic regulation. For example, increased maternal depressive mood during 
pregnancy is associated with reduced methylation of the promotor of the gene 
coding the serotonin transporter (SERT) in both mothers and newborns [60]. These 
results suggest increased SERT mRNA levels and subsequently modified serotonin 
levels, contributing to increased vulnerability later in life [61]. St-Pierre and col-
leagues therefore conclude that all parameters that can alter serotonin homeostasis 
during early development could lead to structural and functional changes in fetal 
development and brain circuits [62], which could subsequently result in a predispo-
sition to psychopathology in adulthood.
Thus, several studies have shown an increased risk for developing the child 
both during antenatal depression and after prenatal SSRI exposure. However, it is 
difficult to discern between the effects of the SSRIs and the effects of the depres-
sion itself, as healthy mothers do not administer antidepressants. For example, 
meta-analyses show that the risk found for ASD in the offspring after prenatal SSRI 
exposure is decreased after correcting for maternal mental illness [63]. Thus, the 
effects of SSRIs mentioned could be solely due to the administration of the SSRIs, 
or alternatively, the SSRIs are only partially effective and therefore do not eliminate 
all the adverse effects of the depression, thereby adding up to the adverse effects of 
antenatal depression [4].
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3. Preclinical studies: perinatal SSRI exposure
In humans, it is difficult, if not impossible, to discern the effects of the SSRI and 
the depression itself on fetal development. It is not ethical to study the effects of 
SSRIs in healthy pregnant women. In addition, it is impossible to study gene expres-
sion and epigenetic changes in the fetal brain as a result of prenatal SSRI exposure. 
Due to these limitations of human research, researchers often use animal models, 
specifically rodents, to get a more profound insight into the mechanisms underlying 
the observations seen in human studies.
It should be noted that the timing of brain development is different in humans 
compared to rodents. A rodent brain at postnatal day 7–10 is considered to be the 
rough equivalent of a newborn human infant [64]. Thus, to mimic SSRI exposure 
during the entire pregnancy in humans, rodents should be exposed both pre- and 
postnatally. In addition, it is known that SSRIs are also found in breast milk [65], 
again underlining the need to research both the effects of pre- and postnatal SSRI 
exposure. For exposure to SSRIs around these time points, we will use the term peri-
natal SSRI exposure; when timing of the SSRI exposure is of particular importance, 
we will distinguish between pre- and postnatal exposure to SSRIs.
3.1 Social behavior
As serotonin is a key regulator of social responses and prenatal SSRI exposure is 
being linked to ASDs, which are characterized by impaired social behavior [54], this 
behavioral parameter is often addressed in researching the effects of prenatal SSRI 
exposure in animals.
Social play at juvenile age is an essential behavior in rodents for the development 
of the necessary social, cognitive, emotional, and physical skills [66]. SSRIs are well 
described in literature as reducing social play behavior in young rats when prenatally 
[67] or postnatally [68–71] administered. These effects of SSRIs seem sex-mediated, as 
males are more affected than females [70], or females are not even affected at all [71]. 
This is interesting because this is analogous to the situation, where men are 3–4 times 
more likely to get diagnosed with ASDs compared to women [72]. In spite of that, not 
all studies found similar results. In a recent study [73], social play behavior was unal-
tered after prenatal SSRI exposure. However, in the latter study, social play was assessed 
with a familiar play partner (littermate), while other studies use a novel conspecific.
Findings on the effects of prenatal SSRI exposure on social behavior at adult age 
are more conflicting. Olivier and colleagues [67] found reduced social exploration in 
adult male rats after prenatal SSRI exposure. While another study found that 4 days of 
postnatal treatment with SSRIs led to increased sniffing, contact with, and total social 
interaction with a novel conspecific in males [74]. On top of that, other studies found 
no effect of prenatal SSRI exposure on social exploration in both males and females 
[75, 76]. In general, studies on the exposure of SSRIs during early development on 
adult social interaction are unconvincing. Studies on social motivation on the other 
hand, measured as the preference of a rodent to spend time with a novel conspecific 
over interaction with an object, appear to be more in line. Decreased social motivation 
is found in both males and females, when postnatally exposed to SSRIs [69–71, 77]. On 
the other hand, prenatal exposure to SSRIs led to an increase in motivation to interact 
with a conspecific in mice [75]. Thus, while literature on the effects of perinatal SSRI 
exposure on social behavior during adult is still limited, both timing of the exposure 
and sex are important factors in the subsequent social development.
Another form of social interaction under the influence of the neurotransmitter 
serotonin is aggression [78]. Indeed, during both childhood and adulthood, SSRIs are 
successfully used to reduce aggressive and violent behavior in certain mental disorders 
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[79, 80]. Perinatal exposure to SSRIs, on the other hand, leads to increased external-
izing behavior, such as aggression, in children [46]. In rodents, the effects of perinatal 
SSRI exposure on aggressive behavior are conflicting. Several studies show an increase 
in male, but not female aggressive behavior [73, 75, 76, 81], while other studies show 
reduced aggressive behavior in male rodents perinatally exposed to SSRIs [82, 83].
Serotonin is known to be involved in the regulation of maternal care [84]. Thus, 
perinatal SSRI exposure can be expected to alter maternal caregiving behavior of 
both the SSRI-treated mother and her female offspring, when they are mothers 
later in life. Typical maternal behaviors include nest building, gathering the young 
into the nest, maternal licking, and nursing the pups. Studies on the effect of direct 
SSRI exposure found an increase in these behaviors [85, 86], or no effect at all [87]. 
So far, only one study has been performed on the effects of prenatal exposure on 
maternal care later in life, and interestingly here, they found a reduction in maternal 
caregiving behaviors [75]. This suggests that direct changes in serotonin levels, such 
as an increase in extracellular serotonin levels during SSRI treatment and changes in 
serotonin levels during development differentially alter the quality of maternal care.
Another role for serotonin is its signaling in sexual development, on both the 
brain and at a behavioral level [88]. In addition, chronic SSRI treatment may result 
in sexual dysfunction [89]. Not much is known on the effect of perinatal SSRI expo-
sure on the sexual behavior of these children later in life; however, several studies 
have been performed in rodents. The effect of perinatal SSRI exposure depends 
on the timing of treatment. When postnatally administered, male sexual behavior 
later in life is reduced [70, 90–93]. In contrast when the SSRI is prenatally, or both 
prenatally and postnatally, administered, there is no effect on sexual behavior of 
male rodents [94, 95]. Interestingly, there appears to be an opposite effect in female 
offspring, where postnatal SSRI exposure leads to an increase in sexual behaviors 
[75, 96]. Thus, apart from the effect of timing, sex of the offspring also differen-
tially alters the effect of perinatal SSRI exposure on reproductive behavior.
3.2 Affective behavior
It has long been established that serotonin is involved in affective disorders [97]. 
Affective disorders, also called mood disorders, include psychiatric disorders such 
as major depressive disorder and anxiety disorders.
A large body of preclinical research has shown the relationship between perinatal 
SSRI exposure and anxiety. Although there are some studies finding no effects, several 
studies did find an increase in anxiety-like behavior and/or less explorative behavior in 
an open field test, when rodents are perinatally exposed to SSRIs [67, 83, 98–104]. An 
increase in anxiety-like behavior in the elevated plus maze and the novelty-suppressed 
feeding test are also found [67, 98, 99, 105]. Nevertheless, there are also studies that 
did not find effects at all [87, 91, 106–111], and two studies even found a decrease in 
behaviors related to anxiety [92, 112]. Even though results differ among studies, these 
differences are not clearly linked to sex of the offspring or timing of the SSRI expo-
sure. So even though there appears to be a clear link between perinatal SSRI exposure 
and anxiety later in life, to get a more profound insight into the mechanisms behind 
this and the role of timing and sex, more researches have to be done.
It is difficult to determine if a rodent is depressed, moreover, to determine if it 
is even possible for rodents to experience depression. However, rodents can show 
behavior characteristics of the behaviors, and humans show during episodes of 
major depression. Such behaviors encompass despair and anhedonia [113]. To 
measure behavioral despair in rodents, the forced swim test is usually performed 
[114]. In this test, the animal is placed in an unescapable container filled with 
water, forcing the rodent to swim. After making efforts to escape the animal may 
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as an increase in extracellular serotonin levels during SSRI treatment and changes in 
serotonin levels during development differentially alter the quality of maternal care.
Another role for serotonin is its signaling in sexual development, on both the 
brain and at a behavioral level [88]. In addition, chronic SSRI treatment may result 
in sexual dysfunction [89]. Not much is known on the effect of perinatal SSRI expo-
sure on the sexual behavior of these children later in life; however, several studies 
have been performed in rodents. The effect of perinatal SSRI exposure depends 
on the timing of treatment. When postnatally administered, male sexual behavior 
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[75, 96]. Thus, apart from the effect of timing, sex of the offspring also differen-
tially alters the effect of perinatal SSRI exposure on reproductive behavior.
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It has long been established that serotonin is involved in affective disorders [97]. 
Affective disorders, also called mood disorders, include psychiatric disorders such 
as major depressive disorder and anxiety disorders.
A large body of preclinical research has shown the relationship between perinatal 
SSRI exposure and anxiety. Although there are some studies finding no effects, several 
studies did find an increase in anxiety-like behavior and/or less explorative behavior in 
an open field test, when rodents are perinatally exposed to SSRIs [67, 83, 98–104]. An 
increase in anxiety-like behavior in the elevated plus maze and the novelty-suppressed 
feeding test are also found [67, 98, 99, 105]. Nevertheless, there are also studies that 
did not find effects at all [87, 91, 106–111], and two studies even found a decrease in 
behaviors related to anxiety [92, 112]. Even though results differ among studies, these 
differences are not clearly linked to sex of the offspring or timing of the SSRI expo-
sure. So even though there appears to be a clear link between perinatal SSRI exposure 
and anxiety later in life, to get a more profound insight into the mechanisms behind 
this and the role of timing and sex, more researches have to be done.
It is difficult to determine if a rodent is depressed, moreover, to determine if it 
is even possible for rodents to experience depression. However, rodents can show 
behavior characteristics of the behaviors, and humans show during episodes of 
major depression. Such behaviors encompass despair and anhedonia [113]. To 
measure behavioral despair in rodents, the forced swim test is usually performed 
[114]. In this test, the animal is placed in an unescapable container filled with 
water, forcing the rodent to swim. After making efforts to escape the animal may 
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eventually stop his efforts and become immobile. The amount of time spent immo-
bile is used as a measure of helplessness and behavioral despair. As reviewed [115], 
many, but not all, studies performing the forced swim test after perinatal SSRI 
exposure found an increase in immobility [83, 99, 100, 105, 106, 109, 110, 116–121]. 
Three studies did not find an effect [67, 87, 111], and three studies even found a 
decrease in immobility [103, 112, 122]. The reviewers propose that these differences 
may be due to strain effects, some strains could be more susceptible to early life 
SSRI exposure, while others are resistant. In addition, they point out that the effect 
of perinatal SSRI exposure is greater, when the animals are exposed during early 
postnatal period rather than the prenatal period.
Anhedonia is another behavior often assessed as a measure for depression. 
Anhedonia is the inability or lack of motivation to experience pleasure from 
rewarding activities and is measured in rodents with the sucrose preference test 
[123]. In this test, two drinking bottles are placed in the rodent’s home cage. One is 
filled with water and the other with a sucrose solution. Preference for the sucrose 
solution is considered as the typical hedonic behavior, and lack of bias toward the 
sucrose water is characterized as a sign of anhedonia. It appears that only postna-
tal SSRI exposure increases anhedonia later in life [124], as opposed to prenatal 
exposure [67, 125]. This once more emphasizes that the moment of exposure is an 
important factor in assessing the effects of perinatal SSRI exposure.
Thus, not only sex of the offspring, but also the timing of the SSRI exposure 
appears to play an important role in behavioral development. However, all aforemen-
tioned studies are performed in offspring from healthy mothers. In practice, pregnant 
women are usually treated with SSRIs when they are suffering from anxiety and/or 
depression. It is likely that both maternal factors and the treatment with SSRIs affect 
serotonin functioning in the embryo and infant. The interplay of these two factors 
might shape the development of the fetus in a different way than antenatal depression 
or prenatal SSRI exposure on its own. Thus, to make a more valid translational step to 
the human situation, animal models of maternal vulnerability have to be used.
4.  Preclinical studies: maternal vulnerability and perinatal SSRI 
exposure
To induce maternal vulnerability in healthy rodents, researchers often use the 
early life stress model (ELS). Maternal separation is one of the manipulations often 
used to create ELS; in this procedure, the offspring is taken away from the mother 
for few hours during the day, and this happens daily during a period of few early 
postnatal weeks. This procedure leads to a long-term and intergenerational increase 
in anxiety and depressive-like behaviors [126–131]. Female offspring exposed to 
ELS and showing an increase in anxiety and depressive-live behaviors can be used 
as a model of maternal vulnerability later in life. Little is known about the interac-
tion of such maternal vulnerability and treatment with SSRIs during pregnancy.
4.1 Social behavior
So far, only two studies have been looking into the combined effects of maternal 
vulnerability and perinatal SSRI exposure on social play behavior and social inter-
action of the offspring later in life. In 2017, Gemmel and colleagues [73] showed 
that the reduction in social play behavior in juveniles due to maternal vulnerability 
is prevented by perinatal SSRI treatment regardless of the sex of the offspring. This 
suggests a rescuing effect of SSRIs on social behavior in offspring of stressed moth-
ers. However, social aggressive play was increased in adolescent offspring exposed 
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to perinatal fluoxetine and maternal vulnerability in both sexes. In addition, time 
grooming a novel conspecific was decreased in males only. In a later study, Gemmel 
and colleagues [132] did not find such an interaction effect on social behavior in 
adult offspring. Even though, maternal vulnerability itself decreased social inves-
tigation in adult males while perinatal SSRI exposure increased social investigation 
in adult females and increased social play in adult males. Thus, normalization, by 
SSRIs, of altered social play and social interaction, due to maternal vulnerability 
might only be short-lived as it does not persist into adulthood. With regard to 
aggression, however, long-term protective effects of SSRIs are found [81]. In this 
study, aggressive behavior was decreased as a result of maternal vulnerability, 
which was normalized when perinatal SSRI exposure was included in the treatment.
One study has looked into the combined effect of SSRI exposure and maternal 
vulnerability on offspring sexual development [133]. Perinatal SSRI exposure 
reduced sexual behavior in male offspring, while interestingly maternal vulnerabil-
ity alone or the combination of maternal vulnerability and perinatal SSRI exposure 
did not have any effect on the development of sexual behavior.
So, even though SSRI treatment of vulnerable mothers appears to have protec-
tive effects on offspring social development, these findings are not consistent over 
all types of behavior and differ with the moment of assessment of the offspring.
4.2 Affective behavior
Affective behaviors of the offspring such as anxiety and depression-like behaviors 
have also been studied after the offspring was exposed to a combination of maternal 
vulnerability and perinatal SSRI exposure. One study [134] shows that the increase 
in anxiety due to maternal vulnerability can be reversed by the postnatal administra-
tion of SSRIs. When prenatally administered, such a rescuing effect is not found 
[87]; however, the effect of maternal vulnerability was limited and was only found 
in males in this study. Two studies assessed depressive-like behavior after perinatal 
exposure to both maternal vulnerability and SSRIs. Both studies found that SSRIs 
normalize the increase in immobility in the forced swim test due to maternal vulner-
ability [87, 135]. Thus so far, the effect maternal vulnerability has on anxiety and 
depressive-like symptoms in the offspring later in life appear to be reversed by SSRIs.
5. Conclusion
Thus, children from mothers who suffer from anxiety or major depression 
during their pregnancy are at risk of developing several psychopathologies later in 
life. Moreover, treatment with SSRIs during pregnancy can also lead to long-term 
consequences for the children. However, it is difficult to determine if these effects 
are due to the SSRI treatment, maternal vulnerability, or a combination of both. 
Preclinical research in rodents shows that perinatal SSRI exposure on itself leads 
to alterations in social behavior later in life. Specifically, social play in juveniles, 
sexual behavior, maternal care in females, and aggression in males are influenced. 
Affective behaviors are also influenced, and both anxiety and depressive-like 
behaviors are increased due to perinatal SSRI exposure. Both the moments of SSRI 
exposure, pre- or postnatal, and sex of the offspring appear to be important factors 
in the development of social and affective behaviors after perinatal SSRI treatment.
Recently, researchers have started to look into the combined effects of maternal 
vulnerability and perinatal SSRI exposure in preclinical studies to make a more 
valid translational step to the human situation. Even though only a few studies have 
been done so far, it seems that, at least some, developmental alterations on offspring 
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behavior due to maternal vulnerability can be normalized by perinatal SSRI expo-
sure. These are interesting and promising results and further investigation into the 
risks and benefits of SSRI use during pregnancy in appropriate animal models are 
necessary to help depressed women in their decision to use SSRIs during pregnancy.
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Abstract
Orexin is a neuropeptide contained in neurons from several hypothalamic nuclei 
that project throughout the forebrain analogously to monoamines synthesized by 
brainstem nuclei. Orexin, like 5-hydroxytryptamine (5-HT), norepinephrine (NE), 
dopamine (DA), histamine and acetylcholine (ACh) exerts prominent effects on 
the sleep-wake cycle of all mammals. Activation of the orexin2 receptor appears 
to induce spontaneous excitatory synaptic currents (EPSCs) on layer V pyramidal 
neurons due to release of glutamate from thalamocortical terminals similar to acti-
vation of 5-HT2A and α1-adrenergic receptors. Layer V pyramidal cells are the major 
descending output cell in the prefrontal cortex with projections to the thalamus, 
striatum, amygdala, brainstem and spinal cord. In keeping with salient modulation 
of prefrontal cortical physiology, orexin2 receptor antagonists exert similar effects 
to 5-HT2A receptor antagonists in suppressing hallucinogen (e.g., DOI)-induced 
head twitches and producing antidepressant-like effects on the differential-
reinforcement-of-low-rate 72-s (DRL 72-s) schedule of reinforcement. Currently, 
there is both negative and some preliminary positive evidence that blocking orexin2 
receptors may result in antidepressant efficacy in patients with major depressive 
disorder. Overall, the treatment of mood disorders is an additional potential indica-
tion for orexin receptor antagonists beyond simply improving sleep.
Keywords: antidepressant drug screens, excitatory postsynaptic potential currents 
(EPSCs), DOI-induced head twitches, differential-reinforcement-of-low-rate 72-s 
(DRL 72-s) behavior, LSN2424100, layer V pyramidal neurons, prefrontal cortex, 
thalamocortical axons
1. Introduction
Only approximately 50–60% of patients experience an antidepressant response 
when treated with selective reuptake inhibitors (SSRIs) or serotonin-norepinephrine 
reuptake inhibitors (SNRIs) [1–3]. Even those patients that do respond often continue 
to experience residual symptoms such as insomnia and cognitive dysfunction [4–7]. 
Thus, novel antidepressant medications are needed that treat a broader expanse 
of symptoms or are effective in patients that have failed several different classes of 
antidepressants drugs.
The primary well-documented augmentation treatment for depressed patients 
already on SSRIs or SNRIs are atypical antipsychotics (aripiprazole, quetiapine, 
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Only approximately 50–60% of patients experience an antidepressant response 
when treated with selective reuptake inhibitors (SSRIs) or serotonin-norepinephrine 
reuptake inhibitors (SNRIs) [1–3]. Even those patients that do respond often continue 
to experience residual symptoms such as insomnia and cognitive dysfunction [4–7]. 
Thus, novel antidepressant medications are needed that treat a broader expanse 
of symptoms or are effective in patients that have failed several different classes of 
antidepressants drugs.
The primary well-documented augmentation treatment for depressed patients 
already on SSRIs or SNRIs are atypical antipsychotics (aripiprazole, quetiapine, 
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risperidone or olanzapine) and less so for mirtazapine/mianserin [8–12]. The 
common pharmacological action shared by these medications is blockade of 5-HT2A 
receptors [13]. Blockade of 5-HT2A receptors may also be a key pharmacological 
feature for most tricyclic antidepressant drugs which explain their greater anti-
depressant efficacy compared to SSRIs [14–17]. However, side effects especially 
problematic for augmentation of SSRIs/SNRIs with atypical antipsychotic drugs are 
weight gain and extrapyramidal symptoms. Thus, discovery of a drug targeted on 
key neurocircuitry modulated by 5-HT2A receptors is one strategy to develop a novel 
antidepressant medication.
Given that pathophysiology of mood disorders appears to involve the prefrontal 
cortex and associated macrocircuits, an obvious candidate brain region to pro-
vide a context for 5-HT2A receptor blockade at augmenting the effects of SSRIs/
SNRIs is the prefrontal cortex [18–21]. In particular, layer V pyramidal neurons 
can effectively modulate important cortical circuits (including corticothalamic, 
corticostriatal, cortico-amydalar and cortico-brainstem) that impact mood, cogni-
tion/executive function, sleep and appetite [22, 23]. One aspect of 5-HT2A receptor 
function largely restricted to layer V pyramidal cells is increasing the frequency 
of spontaneous excitatory postsynaptic currents/potentials (EPSC/EPSPs) onto 
the dendritic branches [24]. This effect appears to be mediated by AMPA receptor 
stimulation of directly on the layer V pyramidal cells [24, 25]. Lesion studies have 
suggested that 5-HT2A receptor activation is releasing glutamate from thalamocorti-
cal terminals arising from the “non-specific” midline and intralaminar thalamic 
nuclei [26, 27]. There appear to be hot spots in layer I and layer Va where focal 
5-HT-induced release of glutamate sensitive to the sodium channel blocker tetrodo-
toxin (TTX) occurs, although an amplification of postsynaptic currents, including 
TTX-sensitive sodium currents [24]. A number of Gi/Go-coupled GPCRs (including 
mGlu2, mGlu4, μ-opioid, adenosine A1 receptors) also suppresses 5-HT- or DOI-
induced glutamate release from these terminals [28–33]. Several other Gq/G11-
coupled GPCRs (α1-adrenergic receptors and mGlu5 receptors) also appear to induce 
glutamate release onto layer V pyramidal neurons that are suppressed by the sodium 
channel blocker TTX, μ-opioid agonists, and AMPA receptor antagonists [34, 35]. 
This rich pharmacological modulation of 5-HT2A receptor-mediated electrophysi-
ological effects on dendritic integration for the principle output neurons in the 
prefrontal cortex provides heuristic promise for drug discovery efforts with respect 
to major psychiatric disease, including mood disorders and schizophrenia [36, 37].
The increase in spontaneous EPSC/EPSPs upon layer V pyramidal cells induced 
by 5-HT2A receptor activation may be associated with other electrophysiological, 
biochemical and behavioral effects involving the medial prefrontal cortex (mPFC). 
On an electrophysiological level, electrical stimulation of the white matter below 
the cortex appears to result in an induction of “late” EPSC/EPSPs during washout 
after application of 5-HT or when the phenethylamine hallucinogen DOI is bath-
applied to the cortical slice [38]. These late EPSCs are also suppressed by a range of 
neurotransmitter receptors that suppress spontaneous 5-HT-induced EPSCs such 
as agonists for mGlu2, μ-opioid, and adenosine A1 receptors [30, 32]. There are 
also some differences between these two electrophysiological responses as NMDA 
receptor stimulation appears important for the electrical stimulation/DOI-evoked 
responses unlike the spontaneous 5-HT-induced EPSC/EPSPs [39].
Secondly, systemic DOI administration also induces a range of immediate-early 
gene-like signals in the prefrontal cortex/neocortex that are also suppressed by 
activation of mGlu2 autoreceptors and appear dependent on glutamate release from 
thalamocortical terminals [40–45]. This effect of prefrontal cortical 5-HT2A recep-
tor activation is relatively sparsely studied compared to the electrophysiological or 
behavioral sequelae.
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Third, either systemic administration or local prefrontal cortical administration 
of agonists for 5-HT2A receptors induces a robust increase in the frequency of head 
twitches (a behavior infrequently observed under baseline condition) [46, 47]. 
Agonists or positive allosteric modulators of mGlu2, mGlu4, μ-opioid, adenosine A1 
receptors also suppress DOI-induced head twitches [28, 31, 48–52]. Naturally, these 
head twitches induced by direct 5-HT2A receptor agonists are also suppressed by 
a number of antidepressant drugs that potently block 5-HT2A receptors or down-
regulate 5-HT2A receptors such as mirtazapine [53], mianserin [54–57], trazodone 
[55, 58–60], nefazodone [58, 61] and tricyclic antidepressants [55, 57, 62–68] Some 
of the tricyclic antidepressants are active only with chronic daily administration. 
While the antidepressant and monoamine oxidase inhibitor (MAOI) tranylcypro-
mine does not directly bind to 5-HT2A receptors, chronic daily administration of 
this antidepressant has been found to suppress 5-methoxy-N,N-dimethyltrypt-
amine-induced head twitches under conditions associated with a down-regulation 
of 5-HT2A receptors [63]. The clinical lore regarding μ-opioid receptor agonists and 
potential antidepressant action is intriguing in light of effects for this class of drugs 
on DOI-induced head twitches have been discussed elsewhere [36].
Finally, an argument was advanced recently that the basis for detecting antide-
pressant-like drug effects on the operant differential-reinforcement-of-low-rate 
72-s (DRL 72-s) schedule may be related to the biology of a range of neurotrans-
mitter systems that interact with the 5-HT2A receptor in the prefrontal cortex to 
modulate motor impulsivity [69, 70]. As expected from the similar effects of 5-HT2A 
receptor antagonists compared to mGlu2 receptor positive allosteric modulators 
(PAMs) and also to adenosine A1 receptor agonists for the prefrontal electrophysi-
ology discussed above, 5-HT2A receptor antagonists, mGlu2 receptor PAMs and 
adenosine A1 receptor agonists all test similar to known antidepressant drugs in rats 
performing under the DRL 72-s schedule [51, 71–77].
The underlying thesis of this chapter is that understanding how other neu-
rotransmitter systems interact with 5-HT2A receptors in the medial prefrontal cor-
tex on an electrophysiological, biochemical and behavioral scale may help discover 
novel antidepressant drugs. Orexin (OX) receptor agonists/antagonists appear to 
be one such neurotransmitter system that interacts with critical biological aspects 
of 5-HT2A receptor activation/blockade in thalamocortical pathways influencing 
the principle output (layer V pyramidal cells) of the prefrontal cortex in a manner 
suggesting that OX2 receptor antagonists are putative antidepressant medications.
2. Orexin-2 receptor blockade and putative antidepressant action
The orexins are two peptide neurotransmitters produced in several nuclei within the  
lateral hypothalamus which are intimately involved in arousal and reward [78]. The 
name “orexin” was originally coined from the Greek word “orexis” when the orexin/
hypocretin peptides were studied for effects on appetite. However, the more salient 
biological aspect of the orexin system later was realized to be altering sleep and 
arousal. More specifically, mutations of genes for the orexin-2 (OX2) receptor, orexin 
peptides, and loss of orexin-containing hypothalamic cell bodies were demon-
strated to be the genetic cause of narcolepsy in canines, mice and humans. The first 
approved medication targeting the orexin system, suvorexant, blocks both orexin-1 
(OX1) and OX2 receptors as a dual orexin receptor antagonist (DORA) and is indi-
cated for the treatment of insomnia [78, 79]. Several other DORAs have been shown 
to be efficacious in treating primary insomnia [80–82]. The overlapping and diverg-
ing distribution for the OX1 and OX2 mRNA and protein has inspired several decades 
of past/ongoing research exploring these receptors for sleep, arousal, feeding, 
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alcohol and drug self-administration, stress, anxiety and depression models [83].  
The involvement of OX2 receptors in arousal together with the presence of OX2 
receptor mRNA in the non-specific midline and intralaminar thalamic nuclei and 
the interactions of the orexin system with brainstem nuclei with overlapping mono-
amine projections makes the OX2 receptor an especially interesting target for mood 
disorder therapeutics [78, 83]. As discussed below, OX2 or hypocretin-2 receptor 
blockade appears to be a mechanism of action that provides a means of testing the 
hypothesis discussed above where a drug appropriately modifying multiple levels 
of biological effects for 5-HT2A receptor activation in the mPFC would be a putative 
antidepressant medication.
Electrophysiological effects of OX2 receptor activation in the prefrontal cortex 
appear to parallel certain effects of 5-HT2A receptor activation when recording 
from layer V pyramidal neurons. The orexin-B (hypocretin-2) peptide was found to 
increase spontaneous EPSC/EPSPs in layer V pyramidal neurons of the prefrontal 
cortex that were blocked by postsynaptic AMPA receptor antagonists as well as by 
TTX and u-opioid agonists on the presynaptic side similar to the case for 5-HT2A 
receptor stimulation [84]. Experiments to delineate the origin of afferents in the 
PFC from which orexin induced glutamate release from suggested that the cells of 
origin were in the midline and intralaminar thalamic nuclei [84]. Further, the rela-
tive potency for orexin-B compared to orexin-A (hypocretin-1) at inducing spon-
taneous OX-induced EPSCs/EPSPs in PFC layer V pyramidal cells is similar to that 
found in the intralaminar and midline thalamic nuclei with OX2, not OX1, receptor 
responses [84–86]. The tetrodotoxin sensitivity of the orexin-induced EPSCs/
EPSPs is in keeping with earlier studies suggesting that thalamocortical projections 
from these “non-specific” thalamic nuclei associated with arousal were prone to 
the generation of terminal spikes as previously suggested [87, 88]. This dependence 
on thalamocortical pathways originating in the midline and intralaminar thalamic 
nuclei and terminating in layers I and Va of the prefrontal cortex is consistent with 
features for the spontaneous 5-HT-induced EPSCs/EPSPs [26, 27]. One difference 
between OX-induced spontaneous EPSCs and 5-HT-induced EPSCS is that OX does 
not appear to induce postsynaptic depolarization (consistent with absence of OX2 
mRNA in layer V pyramidal cells) unlike the case for 5-HT2A receptor activation in 
the majority of layer V pyramidal cells [84, 89]. However, studies characterizing the 
ability of orexin-B induced EPSCs/EPSPs to be blocked with selective OX2 receptor 
antagonists or selective OX1 receptor antagonists would be useful to unambiguously 
identify the OX receptor subtype involved in this response.
Limited work has been done exploring effects of OX2 receptor antagonists on 
immediate early gene (IEG-like) responses in the prefrontal cortex. However, the 
OX2 receptor antagonist LSN2424100 did suppress restraint stress-induced increases 
in c-Fos protein expression without having any effects on baseline Fos protein 
expression in the home cage [90]. These effects of the OX2 receptor antagonist 
LSN2424100 on restraint stress-induced increases Fos expression in the prelimbic 
cortex are similar to an effect of the mGlu2 receptor agonist LY354740 on restraint 
stress-induced increases in Fos expression [45]. As discussed above, 5-HT2A receptor 
agonists induce a number of immediate IEG-like responses in the prefrontal cortex. 
Activation of mGlu2 receptors appears to suppress the DOI-induced increases in a 
number of IEG-like responses in the prefrontal cortex [40, 41, 44, 91].
Modulation of 5-HT2A receptor agonist-induced head twitches is a behavioral 
measure that is suppressed by a range of antidepressants blocking/regulating 
5-HT2A receptors as discussed above; these DOI-induced head twitches are also 
suppressed by the selective OX2 receptor antagonist LSN2424100 (Figure 1). 
LSN2424100 possesses approximately 200-fold functional OX2 receptor antago-
nist activity at both human recombinant OX2 vs. OX1 receptors or rat OX2 vs. OX1 
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receptors [90]. Administration of LSN2424100 (10 mg/kg, i.p.) 30 min prior to 
administration of DOI (3 mg/kg, i.p.) with behavioral observations beginning 
5 min later for a 30 min period resulted in over a 67% statistically significant reduc-
tion in the frequency of DOI-induced head twitches in CD-1 mice (n = 8/group;  
Figure 1) using conditions/methods/statistical analyses reported elsewhere in 
greater detail [52]. Head twitches were observed in 8/8 vehicle/DOI treated mice 
but in only 3/8 LSN2424100/DOI treated mice (p < 0.05, Fisher’s Exact Test). This 
experiment demonstrating that a Gq/G11-coupled GCPR OX2 receptor antagonist 
(like 5-HT2A receptor antagonists) suppress DOI-induced head twitches fits in with 
evidence that agonists or positive allosteric modulators of Gi/Go-coupled GCPRs 
(mGlu2, mGlu4, adenosine A1, and μ-opioid receptors) similarly suppress DOI-
induce head twitches [28, 31, 48, 50, 52, 92, 93]. Thus, the effects of these drugs on 
spontaneous EPSCs/EPSPs upon layer V pyramidal neuron apical dendrites in layers 
I and Va of the prefrontal cortex all produce directionally consistent effects on DOI-
induced head twitches [37]. These results imply that adequate orexin, glutamate, 
adenosine and endogenous opioid release is present from or onto thalamocortical 
afferents under the in vivo experimental conditions employed to engender salient 
changes in dendritic integration of the principle output layer V pyramidal cells.
OX2 receptor antagonists also appear to modulate at least certain aspects of execu-
tive function mediated by the prefrontal cortex, namely impulsivity and biasing oper-
ant responding for DRL schedules in rodents [69, 90]. The OX2 receptor antagonist 
LSN2424100 increased reinforcers obtained and decreased total responses by Sprague-
Dawley rats performing under a DRL 72-s schedule of reinforcement (Figure 2)  
[90]. These antidepressant-like responses were largely replicated in wild-type CD-1 
mice and OX1 receptor knockout mice responding on a DRL 36-s schedule of rein-
forcement rate [90]. However, no changes in the reinforcement rate or response rate 
Figure 1. 
The effect of (±)-DOI (3 mg/kg, i.p.) and the selective OX2 receptor antagonist LSN2424100 (10 mg/kg, i.p.) 
on head twitches in CD-1 wild-type mice observed for 30 min following drug administration. LSN2424100 was 
administered 30 min prior to DOI. Each bar represents the mean (± SEM) of eight mice. Significantly different 
from the mean number of head twitches for the vehicle/DOI group, * p < 0.05. Significantly different from the 
number of mice displaying head twitches for the vehicle/DOI group, # p < 0.05 by the Fisher exact test.
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alcohol and drug self-administration, stress, anxiety and depression models [83].  
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from layer V pyramidal neurons. The orexin-B (hypocretin-2) peptide was found to 
increase spontaneous EPSC/EPSPs in layer V pyramidal neurons of the prefrontal 
cortex that were blocked by postsynaptic AMPA receptor antagonists as well as by 
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in c-Fos protein expression without having any effects on baseline Fos protein 
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Activation of mGlu2 receptors appears to suppress the DOI-induced increases in a 
number of IEG-like responses in the prefrontal cortex [40, 41, 44, 91].
Modulation of 5-HT2A receptor agonist-induced head twitches is a behavioral 
measure that is suppressed by a range of antidepressants blocking/regulating 
5-HT2A receptors as discussed above; these DOI-induced head twitches are also 
suppressed by the selective OX2 receptor antagonist LSN2424100 (Figure 1). 
LSN2424100 possesses approximately 200-fold functional OX2 receptor antago-
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receptors [90]. Administration of LSN2424100 (10 mg/kg, i.p.) 30 min prior to 
administration of DOI (3 mg/kg, i.p.) with behavioral observations beginning 
5 min later for a 30 min period resulted in over a 67% statistically significant reduc-
tion in the frequency of DOI-induced head twitches in CD-1 mice (n = 8/group;  
Figure 1) using conditions/methods/statistical analyses reported elsewhere in 
greater detail [52]. Head twitches were observed in 8/8 vehicle/DOI treated mice 
but in only 3/8 LSN2424100/DOI treated mice (p < 0.05, Fisher’s Exact Test). This 
experiment demonstrating that a Gq/G11-coupled GCPR OX2 receptor antagonist 
(like 5-HT2A receptor antagonists) suppress DOI-induced head twitches fits in with 
evidence that agonists or positive allosteric modulators of Gi/Go-coupled GCPRs 
(mGlu2, mGlu4, adenosine A1, and μ-opioid receptors) similarly suppress DOI-
induce head twitches [28, 31, 48, 50, 52, 92, 93]. Thus, the effects of these drugs on 
spontaneous EPSCs/EPSPs upon layer V pyramidal neuron apical dendrites in layers 
I and Va of the prefrontal cortex all produce directionally consistent effects on DOI-
induced head twitches [37]. These results imply that adequate orexin, glutamate, 
adenosine and endogenous opioid release is present from or onto thalamocortical 
afferents under the in vivo experimental conditions employed to engender salient 
changes in dendritic integration of the principle output layer V pyramidal cells.
OX2 receptor antagonists also appear to modulate at least certain aspects of execu-
tive function mediated by the prefrontal cortex, namely impulsivity and biasing oper-
ant responding for DRL schedules in rodents [69, 90]. The OX2 receptor antagonist 
LSN2424100 increased reinforcers obtained and decreased total responses by Sprague-
Dawley rats performing under a DRL 72-s schedule of reinforcement (Figure 2)  
[90]. These antidepressant-like responses were largely replicated in wild-type CD-1 
mice and OX1 receptor knockout mice responding on a DRL 36-s schedule of rein-
forcement rate [90]. However, no changes in the reinforcement rate or response rate 
Figure 1. 
The effect of (±)-DOI (3 mg/kg, i.p.) and the selective OX2 receptor antagonist LSN2424100 (10 mg/kg, i.p.) 
on head twitches in CD-1 wild-type mice observed for 30 min following drug administration. LSN2424100 was 
administered 30 min prior to DOI. Each bar represents the mean (± SEM) of eight mice. Significantly different 
from the mean number of head twitches for the vehicle/DOI group, * p < 0.05. Significantly different from the 
number of mice displaying head twitches for the vehicle/DOI group, # p < 0.05 by the Fisher exact test.
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were observed in OX2 receptor knockout mice when testing LSN2424100 doses up 
to twice as large as those used for wild-type and OX1 receptor knockout mice [90]. A 
similar antidepressant-like profile was observed in rats, wild-type CD-1 mice, and 
OX1 receptor KO mice with the non-selective OX1/OX2 receptor antagonist almorexant 
[90]. In contrast, a selective OX1 receptor antagonist failed to produce an antidepres-
sant-like response in rats performing on a DRL 72-s schedule or wild type mice or 
OX2 receptor knockout mice responding on a DRL 36-s schedule [90]. However, the 
well-established tricyclic antidepressant drug imipramine tested as expected in these 
experiments as a positive control (e.g., antidepressant-like effects) in Sprague-Dawley 
rats, wild-type mice, OX1 receptor knockout mice, or OX2 receptor KO mice trained to 
lever press under a DRL 72-s schedule (rats) or a DRL 36-s (mice) schedule.
3. Clinical trials with orexin receptor antagonists in patients with MDD
Thus far only a single small double-blind, placebo-controlled, diphenhydr-
amine-controlled, parallel group, phase 1b/2a trial of a selective OX2 receptor 
antagonist, JNJ-42847922/MIN-202 or seltorexant, has been conducted [94]. 
Figure 2. 
The antidepressant-like effect of LSN2424100 on male Sprague-Dawley rats (n = 7) stably performing under 
a DRL 72-s schedule. The top graph shows the effects of LSN2424100 (3–30 mg, i.p.) and imipramine (10 mg/
kg, i.p.) on the number of reinforcers obtained after vehicle/drug was administered 1 hour prior to the daily 
session. The bottom graph shows the effect of LSN2424100 (3–30 mg, i.p.) and imipramine (10 mg/kg, i.p.) on 
the total number of responses. The dotted line shows the control reinforcement and response rate and * denotes 
data points significantly different from control (p < 0.05) (this figure was adapted from data presented by Fitch 
et al. [90]).
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Only 47 men and women with a diagnosis of MDD (DSM-IV) were randomized 
to received either diphenhydramine, 25 mg q.d. (n = 13), seltorexant, 20 mg 
q.d. (n = 22) or placebo (n = 12) for 10 nights. Sleep polysomnography was also 
performed to provide objective assessment of improvements on sleep. There were 
improvements from baseline in the seltorexant treatment group for the HAMD-17 
total score (−3.6 points) as well as the HAM-17 adjusted total score accounting 
for sleep improvement in addition to changes in the HAMD-6 item score (−1.5 
points). This resulted in effect sizes of −0.48, −0.55 and − 1.05 for the OX2 receptor 
antagonist compared to placebo. However, one caveat is that the subjects assigned to 
the histamine H1 receptor antagonist diphenhydramine showed highly comparable 
improvement compared to placebo as did seltorexant. To answer these questions/
concerns, a phase 2b randomized, double-blind parallel group, placebo-controlled, 
adaptive dose-finding trial for seltorexant adjunctive treatment to antidepres-
sants scheduled to enroll about 280 adult subjects at 85 US, European, Russian and 
Japanese sites began in September 2017 (NCT03227224).
The only other MDD clinical trial for an OX receptor antagonist was negative 
[95]. Filorexant (MK-6096), a dual orexin receptor antagonist, was evaluated in a 
6-week, double-blind, placebo-controlled, parallel-group phase 2a proof-of-concept 
trial where subjects with MDD were randomized 1:1 to once-daily oral filorexant 
10 mg or matching placebo. Subjects on antidepressants continued to take their 
prescribed antidepressant for the duration of the trial. This study was stopped 
after enrolling 129 (40%) of a planned 326 subjects. Less than a 1 point numerical 
improvement was observed for filorexant compared to placebo using the mean 
change from baseline to week 6 MADRS total score. Exploratory analyses also 
failed to reveal statistically significant changes in the Insomnia Severity Index (ISI). 
Regarding safety, there were no deaths, drug-related serious adverse events (SAEs) 
and only one discontinuation due to AEs in both treatment groups. There were no 
other problematic safety issues reported.
This negative filorexant MDD study may be related to an issue of inadequate 
power as the planned study was designed with 80% power to detect a 3.5-point 
difference between treatments with a 2-sided 5% level of significance and a fully 
enrolled trial. However, the enrollment of only 129 subjects while using 61 sites 
(United States, Canada, Finland, France, Germany, Norway and Sweden) speaks 
to the recruitment challenges in this study. The dose chosen for this MDD trial 
appears reasonable based on positive effects reported for filorexant in a phase 2 
randomized, double-blind, placebo-controlled adaptive crossover polysomnogra-
phy dose-ranging study evaluating approximately 80 subjects each at nightly doses 
of 2.5, 5 and 10 mg [81]. All doses showed significant effects on sleep efficiency and 
wakefulness after persistent sleep onset while the two higher doses demonstrated 
significant effects on sleep onset. Filorexant was also well tolerated in this insomnia 
trial as well [81].
Preclinical results suggest that the combined OX1/OX2 receptor antagonism 
should not have compromised potential antidepressant action in patients with 
MDD. Namely, the OX1/OX2 receptor antagonist almorexant acted similarly to the 
OX2 receptor antagonist LSN2424100 and the known tricyclic antidepressant imip-
ramine in rats and mice performing on DRL 72-s or DRL 36-s schedules [90]. In 
addition, the non-selective OX receptor antagonist almorexant also tested similarly 
to known antidepressants in mice subjected to unpredictable chronic mild stress 
(UCMS) and then evaluated with the tail suspension test, the resident-intruder 
test, and the elevated plus maze [96]. However, opposing antidepressant-like and 
“pro-depressant”-like effects were observed in OX1 and OX2 receptor knockout 
mice, respectively, studied with the forced swim paradigm [97]. In this same study, 
the selective OX1 receptor antagonist SB-334867 also exerted an antidepressant like 
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were observed in OX2 receptor knockout mice when testing LSN2424100 doses up 
to twice as large as those used for wild-type and OX1 receptor knockout mice [90]. A 
similar antidepressant-like profile was observed in rats, wild-type CD-1 mice, and 
OX1 receptor KO mice with the non-selective OX1/OX2 receptor antagonist almorexant 
[90]. In contrast, a selective OX1 receptor antagonist failed to produce an antidepres-
sant-like response in rats performing on a DRL 72-s schedule or wild type mice or 
OX2 receptor knockout mice responding on a DRL 36-s schedule [90]. However, the 
well-established tricyclic antidepressant drug imipramine tested as expected in these 
experiments as a positive control (e.g., antidepressant-like effects) in Sprague-Dawley 
rats, wild-type mice, OX1 receptor knockout mice, or OX2 receptor KO mice trained to 
lever press under a DRL 72-s schedule (rats) or a DRL 36-s (mice) schedule.
3. Clinical trials with orexin receptor antagonists in patients with MDD
Thus far only a single small double-blind, placebo-controlled, diphenhydr-
amine-controlled, parallel group, phase 1b/2a trial of a selective OX2 receptor 
antagonist, JNJ-42847922/MIN-202 or seltorexant, has been conducted [94]. 
Figure 2. 
The antidepressant-like effect of LSN2424100 on male Sprague-Dawley rats (n = 7) stably performing under 
a DRL 72-s schedule. The top graph shows the effects of LSN2424100 (3–30 mg, i.p.) and imipramine (10 mg/
kg, i.p.) on the number of reinforcers obtained after vehicle/drug was administered 1 hour prior to the daily 
session. The bottom graph shows the effect of LSN2424100 (3–30 mg, i.p.) and imipramine (10 mg/kg, i.p.) on 
the total number of responses. The dotted line shows the control reinforcement and response rate and * denotes 
data points significantly different from control (p < 0.05) (this figure was adapted from data presented by Fitch 
et al. [90]).
91
Orexin 2 Receptor Antagonists from Prefrontal Cortical Circuitry to Rodent Behavioral Screens
DOI: http://dx.doi.org/10.5772/intechopen.82544
Only 47 men and women with a diagnosis of MDD (DSM-IV) were randomized 
to received either diphenhydramine, 25 mg q.d. (n = 13), seltorexant, 20 mg 
q.d. (n = 22) or placebo (n = 12) for 10 nights. Sleep polysomnography was also 
performed to provide objective assessment of improvements on sleep. There were 
improvements from baseline in the seltorexant treatment group for the HAMD-17 
total score (−3.6 points) as well as the HAM-17 adjusted total score accounting 
for sleep improvement in addition to changes in the HAMD-6 item score (−1.5 
points). This resulted in effect sizes of −0.48, −0.55 and − 1.05 for the OX2 receptor 
antagonist compared to placebo. However, one caveat is that the subjects assigned to 
the histamine H1 receptor antagonist diphenhydramine showed highly comparable 
improvement compared to placebo as did seltorexant. To answer these questions/
concerns, a phase 2b randomized, double-blind parallel group, placebo-controlled, 
adaptive dose-finding trial for seltorexant adjunctive treatment to antidepres-
sants scheduled to enroll about 280 adult subjects at 85 US, European, Russian and 
Japanese sites began in September 2017 (NCT03227224).
The only other MDD clinical trial for an OX receptor antagonist was negative 
[95]. Filorexant (MK-6096), a dual orexin receptor antagonist, was evaluated in a 
6-week, double-blind, placebo-controlled, parallel-group phase 2a proof-of-concept 
trial where subjects with MDD were randomized 1:1 to once-daily oral filorexant 
10 mg or matching placebo. Subjects on antidepressants continued to take their 
prescribed antidepressant for the duration of the trial. This study was stopped 
after enrolling 129 (40%) of a planned 326 subjects. Less than a 1 point numerical 
improvement was observed for filorexant compared to placebo using the mean 
change from baseline to week 6 MADRS total score. Exploratory analyses also 
failed to reveal statistically significant changes in the Insomnia Severity Index (ISI). 
Regarding safety, there were no deaths, drug-related serious adverse events (SAEs) 
and only one discontinuation due to AEs in both treatment groups. There were no 
other problematic safety issues reported.
This negative filorexant MDD study may be related to an issue of inadequate 
power as the planned study was designed with 80% power to detect a 3.5-point 
difference between treatments with a 2-sided 5% level of significance and a fully 
enrolled trial. However, the enrollment of only 129 subjects while using 61 sites 
(United States, Canada, Finland, France, Germany, Norway and Sweden) speaks 
to the recruitment challenges in this study. The dose chosen for this MDD trial 
appears reasonable based on positive effects reported for filorexant in a phase 2 
randomized, double-blind, placebo-controlled adaptive crossover polysomnogra-
phy dose-ranging study evaluating approximately 80 subjects each at nightly doses 
of 2.5, 5 and 10 mg [81]. All doses showed significant effects on sleep efficiency and 
wakefulness after persistent sleep onset while the two higher doses demonstrated 
significant effects on sleep onset. Filorexant was also well tolerated in this insomnia 
trial as well [81].
Preclinical results suggest that the combined OX1/OX2 receptor antagonism 
should not have compromised potential antidepressant action in patients with 
MDD. Namely, the OX1/OX2 receptor antagonist almorexant acted similarly to the 
OX2 receptor antagonist LSN2424100 and the known tricyclic antidepressant imip-
ramine in rats and mice performing on DRL 72-s or DRL 36-s schedules [90]. In 
addition, the non-selective OX receptor antagonist almorexant also tested similarly 
to known antidepressants in mice subjected to unpredictable chronic mild stress 
(UCMS) and then evaluated with the tail suspension test, the resident-intruder 
test, and the elevated plus maze [96]. However, opposing antidepressant-like and 
“pro-depressant”-like effects were observed in OX1 and OX2 receptor knockout 
mice, respectively, studied with the forced swim paradigm [97]. In this same study, 
the selective OX1 receptor antagonist SB-334867 also exerted an antidepressant like 
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Figure 3. 
The model where activation of 5-HT2A or OX2 receptors depolarizes and releases glutamate from non-specific 
thalamocortical inputs to layer I and Va of the apical dendrites from layer V pyramidal neurons. The majority 
of 5-HT2A receptors, apart from a minority of presynaptic receptors and those on GABAergic interneurons, are 
present on and also directly depolarize layer V pyramidal neurons. Other glutamatergic receptors (mGlu2 and 
mGlu4), μ-opioid receptors and adenosine A1 receptors that suppress the EPSCs/EPSPs induced by activation 
of 5-HT2A and OX2 receptors appear to be present on non-specific thalamocortical afferents. This circuitry 
(with additional positive modulator receptor such as mGlu5 and NK3 receptors and also additional negative 
modulators such as β2-adrenergic receptors) appears to underlie a similar valence of action for all these 
receptors for a behavior mediated by activation of 5-HT2A receptors in the prefrontal cortex, DOI-induced 
head twitches. This circuitry also appears to underlie impulsive behavior (DRL 72-s behavior) where a similar 
valence of GPCR mediated effects appears to drive antidepressant-like effects on this screening behavior as 
DOI-induced head twitches and 5-HT-induced EPSCs.
effect in the forced swim test. No data has been published suggesting that selec-
tive OX2 receptor antagonists test as antidepressants in rodent forced swim tests. 
Nevertheless, the balance of data are consistent with the hypothesis that adequate 
blockade of both OX1 and OX2 receptors, or OX2 receptors alone, should improve 
depressive symptoms in patients with MDD.
4. Conclusions
Activation of 5-HT2A receptors or OX2 receptors appears to induce glutamate 
release from thalamocortical terminals with cell bodies originating in the midline 
and intralaminar thalamic nuclei when recording from prefrontal cortical layer 
V pyramidal neurons (Figure 3). This 5-HT and orexin-B-induced glutamate 
release appears to dependent action potentials in the presynaptic terminals judging 
from the TTX-induced blockade of the 5-HT- or orexin-induced EPSC/EPSPs as 
93
Orexin 2 Receptor Antagonists from Prefrontal Cortical Circuitry to Rodent Behavioral Screens
DOI: http://dx.doi.org/10.5772/intechopen.82544
suggested previously for non-specific thalamocortical axons. Apical dendritic layer 
V pyramidal AMPA receptors appear to be activated postsynaptic to the thalamic 
terminals. The 5-HT or DOI-induced spontaneous EPSCs/EPSPs or DOI/electrically 
evoked EPSC/EPSPs also appear suppressed by mGlu2, mGlu4, adenosine A1, 5-HT-1-like 
and β2-adrenergic receptors.
Future work is required to establish that orexin-B-induced glutamate release 
from non-specific thalamic afferents is also suppressed by mGlu2, mGlu4, adenosine 
A1, 5-HT-1-like and β2-adrenergic receptors. Blockade of OX2 and 5-HT2A receptors 
also both appear to suppress DOI-induced head twitches, a behavioral response 
that appears to be mediated by activation of prefrontal cortical 5-HT2A receptors. 
A selective OX2 receptor antagonist tested similar to the tricyclic antidepressant 
imipramine in rats and mice responding under an operant DRL 72-s schedule of 
reinforcement. Another question for future preclinical research with rodent DRL 
behavior is whether blockade of OX2 receptors is additive/synergistic with tricyclic 
antidepressants or SSRIs in the same manner as blockade of 5-HT2A receptors. The 
ongoing clinical antidepressant trial with the OX2 receptor antagonist seltorexant 
are important to understanding whether the circuitry involving orexin-containing 
cells in the hypothalamus together with orexin-containing axon terminals in the 
intralaminar and midline thalamic nuclei and the prefrontal cortex are necessary 
and sufficient by themselves to augment the antidepressant effects of tricyclic 
antidepressants and SSRIs. If this ongoing and other clinical antidepressant trials 
with selective OX2 receptor antagonists or additional adequately powered clinical 
trials testing OX1/OX2 receptor antagonists are negative, then future work will be 
required to begin to ask whether additional actions of OX2 receptor antagonists 
in other circuitry are functionally opposed to the brainstem/thalamic/prefrontal 
cortical circuits.
Acknowledgements
The present manuscript was not supported by either Astellas or Lundbeck.
Conflict of interest
The authors were previously employed by Eli Lilly.
Antidepressants - Preclinical, Clinical and Translational Aspects
92
Figure 3. 
The model where activation of 5-HT2A or OX2 receptors depolarizes and releases glutamate from non-specific 
thalamocortical inputs to layer I and Va of the apical dendrites from layer V pyramidal neurons. The majority 
of 5-HT2A receptors, apart from a minority of presynaptic receptors and those on GABAergic interneurons, are 
present on and also directly depolarize layer V pyramidal neurons. Other glutamatergic receptors (mGlu2 and 
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suggested previously for non-specific thalamocortical axons. Apical dendritic layer 
V pyramidal AMPA receptors appear to be activated postsynaptic to the thalamic 
terminals. The 5-HT or DOI-induced spontaneous EPSCs/EPSPs or DOI/electrically 
evoked EPSC/EPSPs also appear suppressed by mGlu2, mGlu4, adenosine A1, 5-HT-1-like 
and β2-adrenergic receptors.
Future work is required to establish that orexin-B-induced glutamate release 
from non-specific thalamic afferents is also suppressed by mGlu2, mGlu4, adenosine 
A1, 5-HT-1-like and β2-adrenergic receptors. Blockade of OX2 and 5-HT2A receptors 
also both appear to suppress DOI-induced head twitches, a behavioral response 
that appears to be mediated by activation of prefrontal cortical 5-HT2A receptors. 
A selective OX2 receptor antagonist tested similar to the tricyclic antidepressant 
imipramine in rats and mice responding under an operant DRL 72-s schedule of 
reinforcement. Another question for future preclinical research with rodent DRL 
behavior is whether blockade of OX2 receptors is additive/synergistic with tricyclic 
antidepressants or SSRIs in the same manner as blockade of 5-HT2A receptors. The 
ongoing clinical antidepressant trial with the OX2 receptor antagonist seltorexant 
are important to understanding whether the circuitry involving orexin-containing 
cells in the hypothalamus together with orexin-containing axon terminals in the 
intralaminar and midline thalamic nuclei and the prefrontal cortex are necessary 
and sufficient by themselves to augment the antidepressant effects of tricyclic 
antidepressants and SSRIs. If this ongoing and other clinical antidepressant trials 
with selective OX2 receptor antagonists or additional adequately powered clinical 
trials testing OX1/OX2 receptor antagonists are negative, then future work will be 
required to begin to ask whether additional actions of OX2 receptor antagonists 
in other circuitry are functionally opposed to the brainstem/thalamic/prefrontal 
cortical circuits.
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Abstract
Low-molecular mimetic BDNF GSB-106, which is a substituted dimeric dipep-
tide, bis(N-monosuccinyl-L-seryl-L-lysine) hexamethylenediamide, was designed 
and synthesized in the V. V. Zakusov Research Institute of Pharmacology. The 
dipeptide activates TrkB, PI3K/AKT, and MAPK/ ERK. GSB-106 is being developed 
as a potential antidepressant. Its antidepressant activity was detected in a number of 
rodent tests (0.1–1.0 mg/kg, ip; 0.5–5.0 mg/kg, po). In the present study, GSB-106 
was shown to completely eliminate the manifestation of anhedonia in the sucrose 
preference test and to increase disturbed hippocampal synaptogenesis at acute oral 
administration (0.1 mg/kg) after 10-day social defeat stress in C57Bl/6 mice.
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1. Introduction
Depression is one of the most widespread mental disorders leading to social dis-
adaptation. According to the WHO data in 2012, there were more than 350 million 
people suffering from depression. Modern antidepressants require long-term use 
to achieve a therapeutic effect, while their effectiveness does not exceed 60% [1]. 
Therefore, the creation of antidepressants with new action mechanisms is regarded 
as one of the most pressing pharmacology problems.
Fundamental studies established that the pathogenesis of depression was associ-
ated with impaired neuroplasticity in the hippocampus and the prefrontal cortex, 
caused by deficit of brain-derived neurotrophic factor (BDNF) [2]. The clinical 
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evidence demonstrates that BDNF levels in blood plasma decrease in depression and 
resolve as the result of antidepressant therapy [3]. A reduced BDNF content in the 
prefrontal cortex and hippocampus was found in suicide victims [4]. The antide-
pressant properties of BDNF were investigated based on its physiological functions. 
The antidepressant effect of neurotrophin was revealed after central administra-
tion in different depression models in rodents [5]. Antidepressant activity was also 
experimentally established for BDNF mimetic 7,8-dihydroxyflavone, an antagonist 
of BDNF-specific TrkB receptors [6].
Following the discovery of antidepressant properties of ketamine, over the 
past decade, a lot of efforts have been made to create new antidepressants with a 
glutamatergic mechanism of action without ketamine-like side effects. To date, 
one of them, rapastinel, a modulator of NMDA receptors, is in a third phase of 
clinical trials [7]. From the theoretical point of view, the most important fact is that 
antidepressant effect of ketamine and other glutamatergic drugs is mediated by 
activation of BDNF-TrkB-Akt-mTORC1-signaling cascade which leads to enhanced 
synaptogenesis [8]. The data proving that mTOR inhibition leads to the disappear-
ance of ketamine antidepressant effects serve as pharmacological confirmation of 
this conclusion [8].
Thus, both pathophysiological evidence and results of experimental and clinical 
pharmacological studies demonstrate the feasibility of using the BDNF-TrkB recep-
tor system as a pharmacological target of search for new antidepressants.
A mimetic of the fourth loop of BDNF, GSB-106, which is a substituted 
dimeric dipeptide, bis(N-monosuccinyl-L-seryl-L-lysine)hexamethylenedi-
amide, was designed and synthesized in the V. V. Zakusov Research Institute 
of Pharmacology [9]. GSB-106 was established to activate BDNF-specific TrkB 
receptors and their main post-receptor signaling pathways—PI3K/AKT and 
MAPK/ERK [10]. GSB-106 demonstrated antidepressant activity at intraperito-
neal (i.p.) (0.1–1.0 mg/kg) and oral (0.5–5.0 mg/kg) administration in a number 
of rodent tests [11, 12]. GSB-106 was also shown to stimulate neurogenesis and 
synaptogenesis in mouse hippocampus [13, 14].
A tablet dosage form of GSB-106 for oral administration was developed in 
the Technological Department of the Institute (application for a patent of the 
Russian Federation 2018107362 from 28 02 2018) to create a drug on the basis of 
the substance. The dosage form of GSB-106 was shown to be active at doses of 
0.01–5.0 mg/kg in forced swimming test in mice and to exceed the “gold standard” 
of antidepressants, amitriptyline, by intensity of effects [11].
The aim of the current study was to investigate antidepressant effects of the 
tablet dosage form of GSB-106 at acute administration in a model of depression-like 
state in mice caused by social defeat stress, in comparison with the widely used anti-
depressant amitriptyline, having affinity to TrkB receptors according to some data 
[15]. This model is considered to be one of the most appropriate, since it reproduces 
the main behavioral and neurobiological signs of depression [16].
2. Materials and methods
2.1 Drugs
GSB-106 (bis(N-monosuccinyl-L-seryl-L-lysine)hexamethylenediamide) was 
synthesized in the Department of Medicinal Chemistry of the V. V. Zakusov Research 
Institute of Pharmacology, as described previously [9]. The tablet dosage form 
of GSB-106 was developed in the Technological Department of the V. V. Zakusov 
Research Institute of Pharmacology, аs described (application for a patent of the 
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Russian Federation 2018107362 from 28 02 2018). The form contained 1% of GSB-
106 and 99% of filler, consisting of lactose, microcrystalline cellulose, polyethylene 
glycol-polyvinyl alcohol copolymer, and magnesium stearate. The tablet dosage 
form of amitriptyline was purchased from Federal State Unitary Enterprise “Moscow 
Endocrine Plant” (Russia).
2.2 Animals
Male adult C57BL/6 mice weighing 18–20 g and male adult outbred mice weigh-
ing 25–28 g were used in the study. The animals were obtained from the “Stolbovaya” 
Central Laboratory for Animal Breeding (Moscow Region, Russia). The animals were 
housed in a vivarium with a natural change of light regime and free access to stan-
dard pelleted food and water. The study was carried out in accordance with the Order 
of the Ministry of Health Care and Social Development of the Russian Federation 
No. 199n of 01 04 2016 “Approval Rules of Good Laboratory Practice” and with the 
Resolution of the Eurasian Economic Commission No. 81 “Concerning adoption of 
the Good laboratory practice of EAEU in the field of drug circulation.” All manipu-
lations with the animals were approved by the Institutional Animal Care and Use 
Committee of the V. V. Zakusov Research Institute of Pharmacology (Moscow).
2.3 Social defeat procedure
A depressive-like state in C57BL/6 mice was created by chronic stress caused by 
repeated experiences of social defeats in daily confrontations between males. The 
social defeat stress was performed as previously reported [6]. The outbred male 
mice were used as aggressors. The C57BL/6 mice and outbred mice were placed 
in pairs into experimental cages (28 × 14 × 10 sm), divided in half by a perforated 
Plexiglas wall, one mouse per compartment. The animals were held in sensory con-
tact in the absence of direct physical interaction for 2 days. Separator was removed 
for 10 min on day 3 to allow animals opportunity for direct contact. Under these 
conditions, the larger outbred mouse acted as an “aggressor.” The confrontation 
was stopped before the expiration of 10 min in the case of overly aggressive attacks 
by the outbred mouse (the bites continued even after the victim mouse had dem-
onstrated a submissive pose). C57BL/6 mice were given daily stress for 10 days as 
described above, which leads to the development of a depressive-like state, accord-
ing to the literature [16].
2.4 Design of the experiment
After 10 days of social defeat stress, the social avoidance test was conducted on 
day 11 to select mice with depressive-like behavior. Then these mice were randomly 
divided into three groups of eight animals each:
The control (stress) group
The “stress + GSB-106” group
The “stress + amitriptyline” group
2.5 Mice were placed into individual cages
On day 12, mice of the “stress + GSB-106” group were orally administered with 
GSB-106 in the dosage form at a dose of 0.1 mg/kg (for the active substance), 
suspended in 1% starch solution; the “stress” group was administered orally with 
1% starch solution; the group of “stress + amitriptyline” was administered orally 
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amitriptyline in the tablet form at a dose of 10 mg/kg, suspended in 1% starch solu-
tion. Three more groups of mice (eight animals per group) not subjected to stress 
were formed simultaneously with the beginning of social stress modeling. On day 
11, these groups were single orally administered with a 1% starch solution (control 
group [no stress]), GSB-106 (the group “GSB-106 [without stress]”) or amitripty-
line (group “amitriptyline [without stress]”) in a 1% starch solution, respectively. 
The dose of GSB-106 was selected based on previously conducted experiments [12]; 
the one of amitriptyline was based on literature data [17]. The sucrose preference 
test was performed on day 13. Mice were decapitated; the hippocampus was isolated 
for subsequent evaluation of the synaptogenesis intensity on day 16. The scheme of 
the experiment is shown in Figure 1.
2.6 The social avoidance test
This test was performed to select mice that developed depressive-like behavior 
as the result of social defeat stress, as described in [6]. The infrared actimeter from 
Panlab (Spain) with ActiTrack software (field size 40.0 × 44.0 cm) was used. An 
individual transparent plastic chamber with holes (8.0 × 8.0 × 8.0 cm) was placed 
at one end of the field of the actimeter. A mouse was placed into the actimeter for 
2.5 min. Then the mouse was returned to the home cage for 30 s. At this time, the 
“aggressor” unknown for the testing mouse was placed in the plastic chamber, and 
the testing mouse was placed in the actimeter for 2.5 min again. The duration of the 
mouse presence in the “interaction zone” (at a distance of 8.0 cm or less from the 
camera with the aggressor) was estimated. The interaction ratio (IR) was calculated 
as the ratio of the time spent in the interaction zone in the presence of the aggressor 
to the time spent in the interaction zone without the aggressor. The value IR < 1 was 
defined as a criterion for depressive-like behavior. Only the mice showing depres-
sive-like behavior in this test (about 90% of the animals) were used in the further 
experiment.
2.7 The sucrose preference test
Mice were exposed to bottles with water and 1% sucrose solution. The consump-
tion of water and sucrose solution was evaluated by weighing the bottles. The 
preference of the sucrose solution was calculated by the following formula:
A(s)/(A(s) + A(w)) × 100%, where A(s) is the amount of consumed sucrose 
solution, g, and W(w) is the amount of consumed water, g. The reduction of this 
parameter below the control group level was regarded as the development of stress-
induced anhedonia [6]. The test was carried out for 18 h.
2.8 Evaluation of hippocampal synaptogenesis
The content of the presynaptic marker synaptophysin in hippocampus was 
assessed using Western blot analysis. After defrost, the hippocampal tissue samples 
were homogenized at 4°C in a glass homogenizer with lysis buffer (50 mM Tris-
HCl, 5 mM EDTA, 1 mM dithiothreitol, 1% Triton X-100, pH 7.5) supplemented 
with a protease inhibitor cocktail (pepstatin, bestatin, leupeptin, and aprotinin, 
“Sigma-Aldrich,” USA), in the ratio of tissue: buffer = 1:10 (weight/volume). 
Then the samples were incubated at 4°C for 20 min and centrifuged at 15,000 rpm 
(Allegra® X-12R centrifuge “Beckman Coulter Inc.,” USA) at the same temperature 
for 20 min. The protein levels of the supernatant lysates were determined by the 
method of Folin-Lowry. The supernatant proteins were separated in a 12% poly-
acrylamide gel and then transferred onto a polyvinylidene fluoride membrane by 
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electroelution. The membranes were deactivated with 5% (w/v) nonfat dry milk 
in Tris buffer containing 1% Tween 20 (TBST) for 1 h. Then, the membranes were 
treated with primary monoclonal mouse antibodies against synaptophysin (“BD 
Biosciences,” United Kingdom) at a dilution of 1:5000 for 1.5 h, the antibody excess 
was washed with TBST with 0.5% (w/v) nonfat dry milk, and the membranes 
were incubated at 37°C with goat antibodies against rabbit IgG (“Santa Cruz 
Biotechnology,” USA, 1:1000), conjugated with horseradish peroxidase, for 1 h. The 
detection of proteins was performed after washing the secondary antibodies with 
TBST buffer in the reaction with enhanced chemiluminescence substrates (ECL 
reagents, Santa Cruz Biotechnology) using the Alliance Q9 gel documenting system 
(UVITEC, United Kingdom). Densitometry of the obtained images was performed 
using the GIMP2 program.
2.9 Statistical analysis
The intergroup differences were assessed using one-way analysis of variance 
ANOVA, followed by post hoc Fisher’s LSD test or the Mann-Whitney U test. 
Differences were considered statistically significant at p ≤ 0.05; the value of p < 0.1 
was regarded as a tendency. The data were presented as mean and standard errors of 
the mean.
3. Results and discussions
One of the main behavioral signs of depression is anhedonia. Anhedonia is 
a violation of the brain “reward system,” it is considered as a key symptom of 
depression both in the International Classification of Diseases of the tenth revision 
(ICD-10) and in the Classification of Mental Disorders of the American Psychiatric 
Association’s Diagnostic and Statistical Manual (DSM-5). A common method for 
assessing anhedonia in animals is the sucrose preference test [6].
In our study the sucrose preference was statistically significantly reduced 
in the stressed mice (the “control [stress]” group) compared with the intact 
animals (the “control [without stress]” group) (Table 1). GSB-106 statistically 
and reliably restored the preference of the sucrose solution to the control level. 
Amitriptyline also restored the preference of the sucrose solution. However, the 
administration of GSB-106 or amitriptyline to intact animals did not affect the 
results of this test (Table 1).
Figure 1. 
The scheme of the experiment.
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(ICD-10) and in the Classification of Mental Disorders of the American Psychiatric 
Association’s Diagnostic and Statistical Manual (DSM-5). A common method for 
assessing anhedonia in animals is the sucrose preference test [6].
In our study the sucrose preference was statistically significantly reduced 
in the stressed mice (the “control [stress]” group) compared with the intact 
animals (the “control [without stress]” group) (Table 1). GSB-106 statistically 
and reliably restored the preference of the sucrose solution to the control level. 
Amitriptyline also restored the preference of the sucrose solution. However, the 
administration of GSB-106 or amitriptyline to intact animals did not affect the 
results of this test (Table 1).
Figure 1. 
The scheme of the experiment.
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Figure 2. 
The synaptophysin level in the hippocampus of mice on the fourth day after the administration of GSB-106 
or amitriptyline. Data are presented as mean ± SEM. Bands: 1, control (without stress); 2, GSB-106 (without 
stress); 3, amitriptyline (without stress); 4, control (stress); 5, “stress + GSB-106”; 6, “stress + amitriptyline.” 
Note: *p < 0.05 compared with the placebo group; #p = 0.08 compared with the stress group (Mann-Whitney  
U test).








the 1% sucrose 
solution, %
Control (without stress) 8 11.4 ± 1.2 2.73 ± 0.5 80.7 ± 3.2
GSB-106 (0.1 mg/kg) 
(without stress)
8 10.08 ± 0.8 2.14 ± 0.3 82.4 ± 2.8
Amitriptyline (10.0 mg/kg) 
(without stress)
8 10.02 ± 0.7 3.47 ± 0.1 74.3 ± 6.5
Control (stress) 8 6.67 ± 0.5 2.12 ± 0.2 75.9 ± 2.4*
Stress + GSB-106 (0.1 mg/kg) 8 10.9 ± 1.1 2.4 ± 0.3 81.9 ± 3.1#
Stress + amitriptyline 
(10.0 mg/kg)
8 13.7 ± 0.9 2.5 ± 0.4 84.8 ± 3.6#
Data are presented as mean ± SEM.
*p < 0.05 comparison with the “control (without stress)” group.
#p < 0.05 comparison with the “control (stress)” group (ANOVA followed by the use of the Fisher’s LSD method).
Table 1. 
The preference of 1% sucrose solution in С57Bl/6 male mice subjected to 10 days of stress, 1 day at acute oral 
administration of GSB-106 or amitriptyline (test duration—18 h).
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Thus, dipeptide mimetics BDNF GSB-106 completely eliminated the mani-
festations of anhedonia at acute administration in mice subjected to 10-day social 
defeat stress.
GSB-106 was previously shown [13] to enhance the synaptophysin content in 
the hippocampus of mice at chronic administration (21 days). In this study, GSB-
106 also caused a statistically significant increase of the synaptophysin content in 
the hippocampus of the control animals after acute administration (Figure 2). In 
stressed animals, synaptophysin content in the hippocampus was reduced by 30% 
compared with nonstressed ones. Such a decrease can be considered as a charac-
teristic sign of a depressive-like state, since the hippocampus is the structure most 
susceptible to pathological changes during depression, as well as the prefrontal 
cortex, and synaptogenesis impairment is considered as one of the main patho-
physiological signs of this disease [2]. The pronounced tendency to restore the level 
of synaptophysin was observed (p = 0.08) at administration of both GSB-106 and 
amitriptyline to the stressed animals (Figure 2).
4. Conclusions
The dipeptide mimetic BDNF GSB-106, like amitriptyline, exhibits anti-anhedo-
nia activity after acute oral administration after 10 days of social defeat stress. The 
effect of GSB-106 was manifested in doses 100 times smaller than amitriptyline, the 
drug of comparison.
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Thus, dipeptide mimetics BDNF GSB-106 completely eliminated the mani-
festations of anhedonia at acute administration in mice subjected to 10-day social 
defeat stress.
GSB-106 was previously shown [13] to enhance the synaptophysin content in 
the hippocampus of mice at chronic administration (21 days). In this study, GSB-
106 also caused a statistically significant increase of the synaptophysin content in 
the hippocampus of the control animals after acute administration (Figure 2). In 
stressed animals, synaptophysin content in the hippocampus was reduced by 30% 
compared with nonstressed ones. Such a decrease can be considered as a charac-
teristic sign of a depressive-like state, since the hippocampus is the structure most 
susceptible to pathological changes during depression, as well as the prefrontal 
cortex, and synaptogenesis impairment is considered as one of the main patho-
physiological signs of this disease [2]. The pronounced tendency to restore the level 
of synaptophysin was observed (p = 0.08) at administration of both GSB-106 and 
amitriptyline to the stressed animals (Figure 2).
4. Conclusions
The dipeptide mimetic BDNF GSB-106, like amitriptyline, exhibits anti-anhedo-
nia activity after acute oral administration after 10 days of social defeat stress. The 
effect of GSB-106 was manifested in doses 100 times smaller than amitriptyline, the 
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